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Background: Survival of neonates requiring respiratory support has improved over 
the last two decades, but unfortunately many suffer morbidity from ventilator related 
complications.  
Aim: To undertake a series of studies using physiological measurements as outcomes 
in infants with evolving or established bronchopulmonary dysplasia (BPD) to test the 
following hypotheses and carry out a national survey.  
Hypotheses:  Proportional assist ventilation (PAV) compared to assist control 
ventilation (ACV) would improve oxygenation as assessed by the oxygenation index 
(OI). Neurally adjusted ventilatory assist (NAVA) compared to ACV would improve 
oxygenation. Use of heated, humidified, high flow nasal cannula (HHFNC) would 
not have increased given the results of recent randomised trials. Continuous positive 
airway pressure (CPAP) would reduce the work of breathing (WOB) and thoraco-
abdominal asynchrony (TAA) and improve oxygen saturation (SaO2) compared to 
HHFNC.  
Methods: Four studies were undertaken. The OI was calculated from measurement of 
blood gases and the level of respiratory support. A survey was undertaken of lead 
practitioners in all UK neonatal units. The WOB was assessed by measurement of 
the pressure time product of the diaphragm (PTPdi) and TAA using respiratory 




Results: The OI was lower on PAV compared to ACV (p = 0.012) and on NAVA 
compared to ACV (p=0.0007). The survey demonstrated HHFNC was used in 56% 
of units in 2012 and 87% in 2015 (p=<0.001). There were no significant differences 
in the WOB, TAA or SaO2 on CPAP versus HHFNC.  
Conclusions: PAV and NAVA may be beneficial in infants with evolving or 
established BPD. Use of HHFNC has significantly increased in UK neonatal units. In 
infants with evolving or established BPD, CPAP compared to HHFNC offered no 
significant advantage and in infants who required respiratory support beyond 34 
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1.1.1 Historical perspective 
 
In the mid-sixteenth century the anatomist and physician, Andreas Vesalius, applied 
positive pressure ventilation to keep the lungs inflated during dissection of the thorax 
(Vesalius, 1543).  It had become evident to the anatomist that it was only necessary 
now and then to blow a little air into the lung of an animal with an opened thorax to 
keep it alive for some time. Robert Hooke went on to describe (Davis, 1665 ), the 
prolonged preservation of life in an open-chested dog by artificial ventilation. He 
showed that a dog could be allowed to ‘die’ and be revived repeatedly by continually 
inflating the lungs with bellows attached to the trachea. 
In 1889, Alexander Graham Bell designed and built a body-type respirator for use in 
new born infants (Stern et al., 1970), but this was met with little enthusiasm and the 
apparatus was probably never used. The tank-type respirator designed by Drinker in 
1929 was used successfully in twenty-one  of thirty-five  new born infants for 
resuscitation of asphyxia at birth by Murphy and his colleagues in 1931(Shaw et al., 
1931). Most of the unsuccessful attempts were in premature babies. In 1950 Alan 
Bloxsom invented the Bloxsom air-lock for new born resuscitation in which the 
infant was enclosed and the box filled with oxygen. The pressure inside was slowly 
cycled (Bloxsom, 1950). There followed 60 years of experimental work with 
individuals designing their own home-made apparatus to assist in the artificial 
ventilation of new born infants. Examples include the work of Ian Donald and his 
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collaborators. In a series of articles (Donald and Lord, 1953, Donald, 1954), they 
described early models of the servo-controlled respirator, designed to augment the 
ventilation of new born infants both acutely and over a period of time (Donald and 
Lord, 1953, Donald, 1954). During this era poliomyelitis was epidemic, and the 
resultant respiratory muscle weakness and bulbar respiratory failure was often 
successfully treated with tank-type negative pressure ventilators of the Drinker 
design or by manually delivered continuous positive pressure through an 
endotracheal tube or tracheostomy. Many polio patients were weaned to a negative 
pressure chest cuirass or to a foot-tilt rocking bed as they improved (Lassen, 1953). 
By 1957, Professor Donald reported treatment of 151 new born infants with his 
successive respirator models, and 50 survived, "A large number of which were under 
three pounds, and even under two pounds” (Donald et al., 1958).  
It was not until 1971 that Gregory (Gregory et al., 1971), an anaesthesiologist, 
developed a method of delivering constant distending airway pressure to the new 
born lung through an endotracheal tube. This system had the possibility of 
maintaining open terminal airways at end expiration, thereby avoiding atelectasis 
when surfactant was deficient and maximising ventilation-to-perfusion ratios. The 
risks of prolonged use of high inspired oxygen concentrations and high peak airway 
pressures were thereby often averted. This concept was added to both positive and 
negative ventilator use, and was further modified by Bancalari who designed a 
constant distending negative pressure chest cuirass (Bancalari et al., 1973) and by 
Kattwinkle who developed nasal prongs to avoid the use of an endotracheal tube 
when a ventilator was not needed (Kattwinkel et al., 1973). Ventilators have now 









Recent estimates of preterm birth rates (all live births before 37 completed weeks) 
for 184 countries in 2010 and a time series for 65 countries with sufficient data 
suggest that 14.9 million (uncertainty range: 12.3 - 18.1 million) babies were born 
preterm in 2010 (Blencowe et al., 2012). Bronchopulmonary dysplasia (BPD) is a 
chronic lung disease (CLD) that most commonly occurs in premature infants who 
have needed mechanical ventilation (MV) and oxygen therapy for acute 
respiratory distress (Northway et al., 1967, Jobe and Bancalari, 2001, Bancalari et 
al., 1979), but can also occur in immature infants who have had few signs of 
initial lung disease (Jobe, 2011). The clinical, radiological, and pathological 
features of BPD were first described  more than five decades ago (Northway et 
al., 1967). BPD was then seen in moderately prematurely born infants with severe 
respiratory distress syndrome who had been treated with high inspired oxygen 
concentrations (Northway et al., 1967). Despite advances in the prevention and 
management of respiratory distress syndrome (RDS) (including the widespread 
use of antenatal steroids and surfactant treatment), BPD is the most common 
adverse outcome of extreme prematurity and hence the prime focus in my thesis 




1.2.2 Prevalence of BPD  
 
BPD in the United States occurs in 10,000 to 15,000 infants annually, including 
approximately 50% of infants with birth weight less than 1000 g (Stoll et al., 2010, 
Martin et al., 2013). The Israeli Neonatal Network reported outcomes for all very 
low birth weight infants (VLBW; birth weight < 1500 g) born in Israel between 2000 
and 2010 who survived to 36 weeks PMA (n =12,139) (Klinger et al., 2013). Based 
on the need for supplemental oxygen at 36 weeks PMA, 13.7% of VLBW and 31% 
of Extremely low birth weight (ELBW) infants met the diagnostic criteria (Klinger et 
al., 2013). In the Canadian and Japanese Neonatal Networks, rates of BPD by 
NICHD criteria for surviving VLBW infants were 12.3% and 14.6% between 2006 
and 2008 respectively (Isayama et al., 2012). 
In the Vermont Oxford Network (VON), yearly rates of BPD for VLBW infants 
ranged from 26.2% to 30.4% between 2000 and 2009 (n=305,770) (Horbar et al., 
2012). In ten European regions, rates of BPD ranged between 10.5% and 21.5% for 
infants born less than 32 weeks gestation in 2003 (Zeitlin et al., 2008). While some 
reports indicate BPD rates are beginning to decline, the majority of studies suggest 
that rates remained stable or are even increasing, possibly due to increased survival 
of the highest risk infants (Smith et al., 2005, Fanaroff et al., 2007, Stoll et al., 2010, 
Stroustrup and Trasande, 2010, Botet et al., 2012, Horbar et al., 2012). Results of the 
EPICure study indicated no change in rates of BPD between 1995 and 2006 for 
infants born between 22 and 26 weeks gestation (Costeloe et al., 2012). Hence, this 




1.2.3 Pathogenesis of BPD  
 
BPD, as it was initially described by Northway in the 1960s, was based on clinical 
and radiographic evidence of pulmonary disease in moderately to late premature 
infants with a history of RDS prior to utilisation of surfactant-replacement therapy 
(Northway et al., 1967). Radiography of these infants showed areas of heterogeneity 
throughout the lung fields and coarse scattered opacities in the most severely 
affected of infants (Bancalari and Gerhardt, 1986). Classic BPD was characterised 
by lung inflammation, airway injury secondary to interstitial and alveolar fluid 
overload, lung parenchyma fibrosis due to hyperinflation and the development of 
small airways disease, smooth-muscle hypertrophy, and oxidative stress (Baraldi and 
Filippone, 2007, Cerny et al., 2008). High ventilator pressures and inspired oxygen 
levels in addition to lack of antenatal steroids and postnatal surfactant, were largely 
responsible for the development of classic BPD (Figure1-1).  
 
There is now growing recognition that infants with BPD after premature birth have a 
different clinical course and pathology than had been recorded before surfactant was 
used (Charafeddine et al., 1999, Rojas et al., 1995). The classic progressive stages 
with prominent fibroproliferation that first characterised BPD are generally less 
striking now  and the disease is now predominantly defined by a disruption of distal 
lung growth, and has been termed the “new BPD”(Jobe, 1999) (Figure1-1). Unlike 
the original form of the disease, this “new” form often develops in preterm newborns 
who may have needed little or no ventilatory support, and have had low inspired 
oxygen concentrations during the early postnatal days (Charafeddine et al., 1999, 
Rojas et al., 1995). Animal studies suggest that the histology of “new” BPD shows 
more diffuse disease, fewer areas of hyperinflation, a reduction in alveoli and 
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capillaries, but little fibrosis (Coalson et al., 1995, Jobe, 1999). At autopsy, the lung 
histology of these infants with the new form has regions of more uniform and milder 
injury, but impaired alveolar and vascular growth remain prominent (Coalson, 2006) 
(Figure1-1). The chest radiograph appearance of new BPD, that is small volume, 
hazy lung fields, is very different from the cystic abnormalities and interstitial 
fibrosis seen in “old” BPD. As a consequence, lung function abnormalities are likely 
to differ according to whether an infant is developing old or new BPD.  
 
Although the pathogenesis of the ‘new BPD’ remains unclear, much evidence 
suggests that this form of chronic respiratory failure reflects abnormal growth and 
repair of the immature lung exposed to the continuous stress of repetitive inflation 
with oxygen rich gas in a setting of chronic inflammation, often aggravated by 
recurrent infection (Pierce and Bancalari, 1995, Zimmerman, 1995). Studies have 
shown an increase in the number of neutrophils, macrophages and neutrophil-derived 
elastase activity in liquid suctioned from the airways of infants with acute RDS who 
later acquire BPD (Ferreira et al., 2000). Studies have also showed that elastase 
inhibitory capacity and 1-protease inhibitor activity are reduced, as is secretory 
leukocyte protease inhibitor (Watterberg et al., 1994), in infants with evolving BPD 
compared to infants without BPD. The reported association of maternal 
chorioamnionitis and early lung inflammation in infants with subsequent BPD 
(Watterberg et al., 1996) led to the notion that BPD sometimes may have a prenatal 








Figure 1-1 Histopathology of Old (A) and New (B) BPD  
(Figure adapted from The New BPD: an arrest of lung development,  (Jobe, 1999)) 
25 
 
1.2.4 Defining BPD  
 
The definition of BPD has continued to evolve since Northway et al. (Northway et 
al., 1967) reported lung damage as a result of prolonged mechanical ventilation in 
premature infants with severe RDS. In 1969 (Pusey et al., 1969), Pusey et al 
described diffuse interstitial fibroplasia associated with mechanical ventilation in 
newborns including patients without RDS. There was no clear relationship 
demonstrated between the use of high oxygen concentration and BPD, thus 
suggesting barotrauma as the primary cause (Pusey et al., 1969). Further definitions 
of clinical BPD have included supplemental oxygen requirement at 28 days postnatal 
age (Kraybill et al., 1989, Sinkin et al., 1990) and 36 weeks postmenstrual age 
(PMA) (Shennan et al., 1988, Marshall et al., 1999).  
 
In 2000, a workshop sponsored by the National Institute of Child Health and Human 
Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI), and 
Office of Rare Diseases (ORD) proposed the current National Institutes of Health 
(NIH) consensus definition of BPD (Jobe and Bancalari, 2001). This definition used 
supplemental oxygen requirement for 28 days and then identified three grades of 
severity, dependent on the respiratory support required at either 36 weeks 
postmenstrual age (PMA) or at discharge for those born at less than 32 weeks 
gestation or at 56 days of life or discharge for those born at more than 32 weeks 
gestation  (Jobe and Bancalari, 2001) (Table 1-1). This definition was validated 
preliminarily with the NICHD Neonatal Network database and data from Palta et al. 
(Palta et al., 2000) and is thought to more accurately identify the risk of adverse 
outcomes than previous definitions (Jobe and Bancalari, 2001). The definition 
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includes a few additional features. First, a day of treatment with supplemental 
oxygen was defined as 12 hours or more of supplementary oxygen exposure. Second, 
infants must require supplemental oxygen for a cumulative of 28 days or more 
before the assessment at 36 weeks PMA. Finally, respiratory support at the time of 
assessment should reflect the infant’s usual therapy in the days surrounding 
assessment and not an “acute” event. Studies that rely on a simple “snapshot” of 
respiratory support at 28 days or 36 weeks PMA may therefore incompletely assess 
BPD rates based on those criteria (Bancalari et al., 2003). To decrease variability in 
BPD diagnosis, Walsh et al.(Walsh et al., 2003) proposed a “physiologic” definition 
which required an oxygen reduction test to determine oxygen dependency. To 
conduct the test, the fraction of administered oxygen was reduced in a stepwise 
manner over a defined timed interval. Infants who are unable to maintain saturations 
≥ 90% during that time were diagnosed with BPD. Ehrenkranz et al. (Ehrenkranz et 
al., 2005) attempted to validate the accuracy of the NIH consensus definition of BPD 
in a cohort of extremely low birth weight (ELBW; birth weight<1000 g) infants 
followed in the NICHD Neonatal Research Network’s very low birth weight registry.  
The Jobe and Banclari (Jobe and Bancalari, 2001) definition was more accurate in 




Table 1-1: Diagnostic classification of BPD into mild, moderate and severe 
based on gestational age and respiratory support requirement. 
(Adapted from the National Institutes of Health Consensus Definition of 
Bronchopulmonary Dysplasia (Jobe and Bancalari, 2001))  
 
BPD classification 
Gestational age Mild Moderate Severe 
< 32 weeks 
Treatment with  
> 21% oxygen 
for 28 days plus 
no respiratory 
support at 36 
weeks PMA or 
discharge home 
Need for < 30% 
oxygen at 
36weeks PMA or 
discharge home 
Need for ≥ 30% 
oxygen and/ or 
positive pressure 
ventilation or 
CPAP at 36 
weeks PMA or 
discharge home 
≥ 32 weeks 
Treatment with  
> 21% oxygen 
for 28 days plus 
no respiratory 
support at 56 
days Postnatal 
age (PNA) or 
discharge home 
Need for < 30% 
oxygen at 56 
days PNA or 
discharge home 











1.2.5 Risk Factors for BPD 
 
The aetiology of BPD is multifactorial and involves exposure to prenatal and/or 
postnatal factors, which disrupt pulmonary development, and may cause 
inflammation and damage to the highly vulnerable premature lung (Jensen and 
Schmidt, 2014). 
 
Figure 1-2: Stages of lung development, potentially damaging factors, and types 
of lung injury.  
Adapted from From Eugenio Baraldi, M.D.; Marco Filippone, M.D. Chronic Lung 
Disease after Premature Birth (Baraldi and Filippone, 2007). N. Engl. J. Med. 2007, 
357, 1946–1955.  
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1.2.5.1  Prenatal Risk Factors 
 
1.2.5.1.1 Intrauterine growth restriction 
Fetal growth restriction in infants with a gestational age below 28 weeks appears to 
be an independent risk factor for BPD (Bose et al., 2009, Torchin et al., 2016). The 
extremely low gestational age newborn (ELGAN) study found a strong association 
between fetal growth restriction and BPD in infants born less than 29 weeks 
gestation (Bose et al., 2009). Odds of BPD in that cohort were over threefold higher 
for infants with birth weight more than one standard deviation below the mean (Bose 
et al., 2009). In a case-control study that included 2255 infants less than 33 weeks 
gestation, infants born small for gestational age had more than twice the risk of BPD 
(Odds ratio (OR) 2.73, 95% Confidence Interval (CI) 2.11-3.55) (Eriksson et al., 
2015). Klinger et al. (Klinger et al., 2013) reported the risk-adjusted odds for BPD of 
2.65 (95% CI, 2.24–3.12) in VLBW infants with birth weight (BW) less than the 
10% for gestational age (GA). 
 
1.2.5.1.2 Chorioamnionitis 
Whether maternal chorioamnionitis increases BPD risk remains controversial. A 
study (Van Marter et al., 2002), reported decreased rates of BPD in VLBW infants 
exposed to chorioamnionitis, except in those who subsequently developed sepsis. 
Odds of BPD in those cases were nearly threefold higher (OR, 2.9; 95% CI, 1.1 7.4). 
Similar decrease in BPD with histologic chorioamnionitis alone was also present in 
another study but an increase when postnatal sepsis (Lahra et al., 2009). The 
unreliability of both clinical and histologic diagnoses of chorioamnionitis make the 
interpretation of available data difficult (Redline et al., 2003, Jobe, 2012). The 
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ELGAN study which  aimed to identify factors that contribute to brain damage, 
reported that while 51% of placental cultures obtained from 1119 extremely preterm 
deliveries yielded positive results (Bose et al., 2009). Chorioamnionitis in fetal mice 
stimulated angiogenesis and produced an inflammatory profile comparable to the 
inflamed lungs of infants developing BPD (Miller et al., 2010). Infants exposed to 
severe chorioamnionitis had lower clinical responses to surfactant treatment and 
those lower responses correlated with longer mechanical ventilation and more BPD 
(Been et al., 2010). A meta-analysis of studies involving 13,583 infants found that 
histologically but not clinically diagnosed chorioamnionitis was associated with 
higher odds (OR 1.89, 95% CI 1.56 to 2.3) of BPD (Hartling et al., 2012).  
 
1.2.5.1.3 Genetics  
Several investigators have attempted to identify associations with BPD of molecules 
or pathways that are known to be associated with lung development, maturation, 
inflammation, fibrosis, angiogenesis, oxidative stress, or tissue injury and repair. In 
general, many of these studies have focused on single nucleotide polymorphisms 
(SNPs) in relatively few genes or pathways, and have had limited sample sizes from 
one or a few centres (Hallman and Haataja, 2006, Lahti et al., 2004, Sorensen et al., 
2014). A limitation of these approaches is that we currently do not have a good 
understanding of the regulation of the transition from the saccular to the alveolar 
stage of lung development. Hence, we do not know all the molecules or pathways of 
critical importance to distal lung development (and therefore to BPD pathogenesis) 
that can be targeted for analysis. Twin studies provide insight into genetic 
predispositions as monozygotic twins share 100% of their genetic information while 
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dizygotic twins are 50% concordant (Shaw and O'Brodovich, 2013). A total of 450 
twin pairs were analysed using mixed-effects logistic-regression and a latent variable 
probit model in a multicentre retrospective study. This analysis concluded that 65% 
of the variances in BPD susceptibility could be accounted for by genetic and shared 
environmental factors (Bhandari et al., 2006). Subsequent multicentre studies 
confirmed the heritability of BPD by way of data identifying greater similarity in 
monozygotic as compared to dizygotic twins. One series of over 300 twins reported 
that genetics contributed to approximately 80% of the observed variance in rates of 
BPD (Lavoie et al., 2008). More recently, several genome-wide association studies 
(GWAS) have been conducted to identify candidate SNP’s associated with BPD. The 
largest study evaluated over 1700 infants and failed to identify genomic loci or 
pathways that accounted for the previously described heritability for BPD (Wang et 
al., 2013). A second, smaller analysis (n=418) concluded that the SPOCK2 gene may 
represent a possible candidate susceptibility gene and a key regulator of 




1.2.5.2  Risk Factors At Birth 
 
1.2.5.2.1 Gestational age  
GA is inversely proportional to the incidence of BPD, as well as the severity of the 
disease. Among infants meeting the physiological definition of BPD at 36 weeks 
postmenstrual age (PMA), 95% were very-low-birth-weight (VLBW) (Walsh et al., 
2004). In the NICHD network, the incidence of BPD at 23 weeks PMA (as defined 
as oxygen at 36 weeks PMA) was 73% with 56% of infants having severe BPD. In 
comparison, at 28 weeks PMA the incidence of BPD was 23% with only 8% of 
infants with severe BPD (Stoll et al., 2010).  In the NICHD Neonatal Research 
Network, the incidence of BPD in infants born at 23 weeks gestation was 73%, 56% 
of whom developed severe disease (Stoll et al., 2010). At 28 weeks gestation, 23% 
develop BPD, with severe disease found in only 8% (Stoll et al., 2010). 
The Canadian Neonatal Network reported that 28.1% of surviving infants born 
less than 25 weeks gestation developed BPD (defined as oxygen use at 36 weeks 
PMA following oxygen use on the 28th day after birth) compared with only 4% of 
infants born at 29 to 32 weeks gestation (Isayama et al., 2012). In an Israeli 
national cohort, 50.1% of surviving infants born at 24 to 25 weeks gestation 
developed BPD diagnosed by oxygen requirement at 36 weeks PMA compared 






Male infants are at increased risk of BPD compared with females of similar GA and 
BW (Palta et al., 1991, Rojas et al., 1995, Ambalavanan et al., 2008, Costeloe et al., 
2012). Among VLBW infants enrolled in the NICHD trial of inhaled nitric oxide, the 
adjusted odds of BPD or death were nearly five times greater for males than females 
(Ambalavanan et al., 2008). Surviving males in the EPICure studies were over twice 




1.2.5.3  Postnatal Risk Factors 
 
1.2.5.3.1 Supplementary oxygen 
 
1.2.5.3.1.1 Delivery room resuscitation 
 
Several studies of delivery room resuscitation and early respiratory management 
evaluated whether interventions aimed at reducing mechanical ventilation and 
supplemental oxygen exposure result in improved respiratory outcomes. In a small 
randomised control trial (RCT), (Vento et al., 2009), infants born between 24 to 28 
weeks gestation those, resuscitated in the delivery room with 30% (n=37) and 
compared to those with 90% (n=41) supplemental oxygen had a lower incidence of 
BPD (31.7% vs 15.4%; p < 0.05). The Room Air versus Oxygen Administration 
During Resuscitation of Preterm Infants (ROAR) study (Rabi et al., 2011), however, 
found no difference in BPD rates between preterm infants treated with room air 
(n=34), titrated oxygen (n=34), or 100% supplemental oxygen (n=38) (Rabi et al., 
2011). In another study (Kapadia et al., 2013), BPD in infants with gestational age of 
24 to 34 weeks were randomised to two different delivery room resuscitation 
strategies. In one arm (n=44), resuscitation was initiated with room air and 
supplemental oxygen was titrated to achieve the neonatal resuscitation program 
(Kattwinkel et al., 2010) recommended saturation levels. The alternate arm (n=44) 
titrated from 100% supplemental oxygen to achieve a saturation of 85 to 94%. BPD 
rates were lower in the infants initially resuscitated without supplemental oxygen 




1.2.5.3.1.2 Target oxygen saturation  
 
Extensive efforts have been made to define optimal saturation targets for premature 
infants (Manja et al., 2015). A meta-analysis including five separate trials did not 
identify significant differences in the outcomes of visual disability following 
retinopathy of prematurity or BPD but raised concerns for increased risk of mortality 
at 18 – 22 month corrected gestational age (CGA) with lower saturation targets (low 
85%-89% versus high 91% – 95%) as well as higher rates of necrotizing 
enterocolitis (NEC) (Stenson, 2016, Saugstad and Aune, 2014). Specific to the 
outcome of BPD, the Surfactant, Positive Pressure and Oxygenation Randomization 
Trial (SUPPORT) found non-significant  lower rates of BPD (38% versus 41.7%) in 
the low-saturation group (Network et al., 2010a). The Canadian Oxygen Trial (COT) 
identified a similar trend with BPD rates of 31.8% and 33.1% in the low- and high-
saturation groups, respectively (Schmidt et al., 2013). Finally, the three trials 
conducted in New Zealand, the UK and Australia combined as the Benefits of 
Oxygen Saturation Trials (BOOST II) found similar non-significant trends with rates 
of 39.5% and 44.7% in the low- and high-saturation groups respectively (Group et 
al., 2013, Stenson et al., 2011). Use of higher saturation targets will inherently 
increase documented rates of BPD as infants cannot be weaned until they can 
maintain these higher goals. Nonetheless, the meta-analysis including all five studies 
still failed to identify a significant difference in rates of oxygen requirement at 36 
weeks (Saugstad and Aune, 2014). Despite the theoretical concerns for increased risk 
of oxidative lung injury and pulmonary vascular remodelling, many units now use 
higher saturation limits of 91%-95% based upon the collective finding of improved 
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survival in these five trials. Some suggest that higher targets of 93% – 97% should 
be considered with established BPD to reduce risks of subsequent pulmonary 
hypertension (Cummings et al., 2016).  
 
1.2.5.3.2 Permissive Hypercapnia  
 
Permissive hypercapnia is a ventilatory strategy that permits relatively high levels of 
partial pressure of arterial carbon dioxide (PaCO2) and always used to avoid lung 
injury and BPD (Miller and Carlo, 2007). Four studies that enrolled a total of 693 
participants selected to a meta-analysis (Mariani et al., 1999, Carlo et al., 2002, 
Thome et al., 2006, Thome et al., 2015), revealed no effect of permissive 
hypercapnia on decreasing rates of bronchopulmonary dysplasia (BPD). Permissive 
hypercapnia also had no significant effect on mortality, intraventricular haemorrhage 
(IVH), IVH (grade 3–4), periventricular leukomalacia (PVL), necrotising 
enterocolitis (NEC), and retinopathy of prematurity (ROP) or air leaks in extremely 




1.2.5.3.3 Patent ductus arteriosus  
 
The role of a patent ductus arteriosus (PDA) in the development of BPD is much-
debated. There is evidence to support an association but not a causal relationship 
between persistent PDA and BPD (Benitz, 2010, Benitz, 2012, Trzaski et al., 
2012). Studies of prophylactic closure of PDA showed no benefit for prevention 
of BPD and some suggest that treatment may increase BPD risk (Cooke et al., 
2003, Fowlie et al., 2010, Ohlsson et al., 2013). In the Trial of Indomethacin 
Prophylaxis in Preterm (TIPP) (Schmidt et al., 2001), Indomethacin reduced the 
incidence of PDA (24% vs. 50% in the placebo group; odds ratio, 0.3; p<0.001) 
and severe Periventricular Haemorrhage (PVH) and IVH (9%, vs. 13% in the 
placebo group; odds ratio, 0.6; p = 0.02). No other outcomes were altered by the 
prophylactic administration of indomethacin. In a follow-up to the TIPP study, the 
treatment did not prevent BPD, although it reduced the frequency of PDA 
(Schmidt et al., 2006). BPD rates were considerably lower (30% vs. 43%) in 
infants in whom PDAs closed spontaneously without indomethacin compared 
with those with closure following indomethacin (Schmidt et al., 2006). A recent 
Cochrane Review found no difference in the incidence of BPD following medical 
versus surgical closure of PDA in preterm infants, but the analysis contained only 
a single small RCT (Malviya et al., 2013). In a subsequent systematic review of 
all RCTs evaluating both surgical and pharmacologic methods of PDA closure, 
Benitz (Benitz, 2010) found no reduction in BPD or the combined outcome of 




1.2.5.3.4 Infection and Inflammation  
There exists controversy regarding the contribution of postnatal inflammation or 
nosocomial infection to the increased risk of developing BPD (Oh et al., 2005, 
Lahra et al., 2009, Klinger et al., 2010). Novitsky et al. identified that premature 
infants with BPD were more likely to receive prolonged courses of antibiotics in 
the first week after birth and to have evidence of resistant gram-negative bacilli in 
their endotracheal tube (Novitsky et al., 2015). Those data raises concerns that the 
presence of resistant organisms may result in more severe infection, advocating 
for judicious use of prophylactic or prolonged antibiotics in premature infants at 
risk. Non-infectious exposures, including oxygen and mechanical ventilation, 
cause further injury to the preterm lung resulting in secondary insult via 
inflammatory mediated responses. Increased pro-inflammatory cytokines found in 
tracheal aspirates and blood samples from premature infants, including tumor 
necrosis factor alpha (TNFα), IL-8, IL-1β and IL-6, have been shown to correlate 
with increased risk of BPD (Tullus et al., 1996, Jonsson et al., 1997, D'Angio et 




1.2.5.3.5 Postnatal corticosteroids 
 
The potential benefits of systemic steroids are often outweighed by concerns for 
long-term neurodevelopmental sequelae including increased risk of cerebral palsy 
(CP) (Halliday, 2002, Halliday et al., 2009). Rates of use of systemic steroids for 
prevention of BPD have markedly decreased following American Academy of 
Pediatrics (AAP) and Canadian Pediatric Society (CPS) recommendations in 2002 
against routine use (Jarreau et al., 2010, Yoder et al., 2009). Specifically, rates of 
postnatal corticosteroids use declined from 20% in 1997 – 2000 to only 12% in 2001 
– 2002 and then again to 8% in 2004 with no significant change thereafter (Fanaroff 








In a study of 238 infants who were born at less than 33 weeks gestation, 49% of 
infants with BPD required readmission during the first year after birth compared 
with 23% of non-BPD infants (Smith et al., 2004). The mean number of 
readmissions and length of stay were also greater for infants with BPD (Smith et al., 
2004). During the first two years, Greenough et al. (Greenough et al., 2001)  reported 
that 57% of infants with BPD required re-hospitalisation for respiratory problems. 
Respiratory syncytial virus infection in particular was associated with higher 
readmission rates (Greenough et al., 2001, Drysdale et al., 2011). In the NICHD 
Neonatal Research Network, rates of rehospitalisation and pulmonary medication use 
at 18 to 22 months increased with increasing severity of BPD (Ehrenkranz et al., 
2005). During the second and third year of life, re-hospitalisation rates decline, 
although BPD survivors may remain at increased risk for respiratory related 




1.2.6.2 Respiratory symptoms 
 
Many survivors of BPD demonstrate a component of reactive airway disease. 
Problematic respiratory symptoms, such as wheezing and coughing, can continue 
into preschool years (2-5 years) (Greenough et al., 2006). In a cohort of 308 
extremely preterm infants followed through six years of life, wheezing, coughing, 
and use of inhaled medications were significantly more common in those with than 
without BPD (Hennessy et al., 2008). At 11-year follow-up of infants from the same 
cohort, 28% with a history of BPD were diagnosed with asthma, 24% suffered 
exercise induced wheezing, and 22% experienced nocturnal cough (Fawke et al., 
2010). Cough, wheeze, and dyspnoea are also common in young adult survivors with 
BPD (Gough et al., 2012). Lung function abnormalities and respiratory symptoms 
can continue into adulthood. A study of 690 adults who had developed BPD as 
infants (Vrijlandt et al., 2005) highlighted that compared to controls, wheezing 
without a cold, asthma diagnosis and shortness of breath on exercise were more 
common, but only in the female population.  
Long-term follow-up of infants born less than 26 weeks of gestation identified that 
25% had an asthma diagnosis at 11 years of age while over twice this percentage 
(56%) had evidence of abnormal spirometry (Fawke et al., 2010). Cohort studies 
show a significantly greater prevalence of asthma like symptoms and the use of 
inhaled asthma medication among persons 8 to 19 years old who were born 
prematurely regardless of whether they had BPD than among persons born at term 
(Doyle et al., 2006, Anand et al., 2003, Halvorsen et al., 2004). A trend toward 
clinical improvement is usually seen over time, however; symptoms progressively 
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subside, respiratory exacerbations become uncommon, and most persons lead 
apparently normal lives (Kinsella et al., 2006).  
While children with BPD have asthma-like symptoms, they are also less likely to 
demonstrate airway hyper-responsiveness or response to bronchodilators as they may 
suffer a fixed peripheral airway narrowing (Joshi et al., 2013). In addition, co-morbid 
bronchomalacia or other central airway disease in ex-premature infants can result in 
exacerbated wheezing with use of bronchodilator therapy (Allen et al., 2003). 
Benefits from inhaled corticosteroids are also thought to be less consistent for 
children with BPD as compared to those with asthma (Allen et al., 2003). The 
reversibility and impact of this asthma - like phenotype on late adult pulmonary 
morbidity remains unknown. 
 
1.2.6.3  Pulmonary function 
 
In most infants with BPD, lung growth and remodelling during infancy results in 
progressive improvement of pulmonary function and weaning from oxygen 
therapy; few BPD patients remain oxygen-dependent beyond two years of age 
(Greenough et al., 2004). Several studies in infants (aged 6 to 12 months) with 
BPD have demonstrated evidence of small airway disease and impaired alveolar 
growth. Lung function is usually in the low-to-normal range by age two to three 
years, but airflow abnormalities can remain. In another study, sequential 
measurements during the first two to three years following hospital discharge 
demonstrated gradual increases in FRC (mL/kg) from initial low levels to more 
normal levels, but with persistent limitations of maximum flow at FRC 
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(VmaxFRC) (Fakhoury et al., 2010). Approximately one-third of those patients 
responded to bronchodilators (Fakhoury et al., 2010).  
Although clinical symptoms in individuals with BPD often improve during 
childhood, pulmonary function tests (PFTs) often remain abnormal, particularly in 
those with more severe disease (Baraldi and Filippone, 2007, Ronkainen et al., 
2015). One study (Filippone et al., 2003), reported a strong correlation between 
VmaxFRC at two years of age and FEV1 at school age (mean 8·8 years), 
suggesting persistent airflow limitation in some patients with BPD. Another study 
compared preschool children with healthy controls and found decreased forced 
expiratory volume in one second (FEV1), increased FRC, residual volume (RV), 
and the ratio of RV to total lung capacity (RV/TLC) in the BPD group consistent 
with obstructive lung disease (Robin et al., 2004). Those findings are consistent 
with persistent airflow obstruction and gas trapping. A retrospective review of 
322 preterm infants with BPD (Landry et al., 2011) demonstrated that lung 
function as assessed by forced expiratory volume, forced vital capacity and forced 
expiratory fraction was significantly reduced at seven  years of age compared to 
controls. They also observed that lung function abnormalities and health-care 
utilisation during childhood was significantly associated with the initial severity 
of BPD. In many patients, especially those with mild disease, pulmonary function 
tests (PFTs) gradually improved over time, possibly in conjunction with new 
alveolar development and improvement in small airway flow limitation (Baraldi 
et al., 1997, Fakhoury et al., 2010, Gerhardt et al., 1987).  
There are few data on the pulmonary function of adult patients with a history of 
premature birth and old BPD. Long-term respiratory morbidity is not limited to 
BPD survivors born before routine surfactant use. BPD survivors from the 
EPICure cohort, 89% of whom received surfactant, suffered significantly 
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decreased lung function at 11 years of age compared with extremely preterm and 
term controls without BPD (Fawke et al., 2010). Abnormalities in PFTs are 
commonly found in children and adults with BPD (Doyle et al., 2006, Landry et 
al., 2011, Doyle and Anderson, 2009). PFTs frequently show decreased FEV1 and 
decreased ratios of FEV1 to forced vital capacity (FEV1/FVC), consistent with 
airflow limitation and small airway obstruction (Doyle et al., 2006, Landry et al., 
2011).  
A recent systematic review of adults born during the pre-surfactant era found 
higher rates of pulmonary function abnormalities and radiographic evidence of 
persistent structural changes in the lungs of those with a history of BPD (Gough et 
al., 2012). Another study  compared lung function at eighteen years of age in two 
cohorts of ELBW infants, one born before and the other after availability of 
surfactant. Significant airway obstruction was found in preterm survivors from 
both cohorts, with airflow limitations most pronounced in those with a history of 




1.2.6.1 Pulmonary Hypertension  
 
Complications of BPD include pulmonary hypertension (PH), due to anatomical 
and physiological abnormalities in lung circulation in BPD patients, which 
contributes significant mortality and morbidity in BPD patients (Kim, 2010). 
While the true incidence of pulmonary arterial hypertension in infants with BPD 
is unknown, several small retrospective reports estimate rates at 25% to 37% (An 
et al., 2010, Slaughter et al., 2011, Kim et al., 2012, Check et al., 2013). Forty-
five percent of infants who required supplemental oxygen at 36 weeks PMA were 
diagnosed with PH. The incidence of PAH increased with increasing BPD 
severity. Only 2% of infants with mild BPD had evidence of pulmonary arterial 
hypertension compared with 36% with moderate and 50% with severe BPD (Bhat 
et al., 2012). In a series of 42 VLBW infants with BPD and PAH, mortality was 
38% during a median follow-up period of 10.9 months and only 25% with severe 
PH and BPD survived to two to three years of age (Khemani et al., 2007). Among 
all survivors with BPD and pulmonary arterial hypertension, however, 89% 
demonstrated improvement in pulmonary arterial hypertension during the follow-




1.3 Ventilator-induced lung injury (VILI) 
 
Ventilator-induced lung injury (VILI) is a common complication of MV in 
premature infants and may predispose the infant to abnormal lung growth and 
development and BPD (Attar and Donn, 2002). Several mechanisms may contribute 
to the lung injury that is associated with MV. These mechanisms are not mutually 
exclusive and may act synergistically. Understanding these mechanisms may have 




Barotrauma occurs when high pressures are used in ventilation, thus increasing the 
risk of air leak syndromes, such as interstitial emphysema, pneumothorax, and 
pneumomediastinum (Morisot et al., 1990), which in turn activate the inflammatory 
cascade (Carvalho et al., 2013).  In a study (Webb and Tierney, 1974), anaesthetised 
rats were ventilated with room air at peak inspiratory pressures of 14, 30 or 45 
cmH2O without any added PEEP, while other rats were ventilated with the same 
inspiratory pressures but with an added PEEP of 10 cmH2O. The results showed that 
the control group of rats that were not ventilated and the group of rats ventilated with 
pressures of 14/0 showed no pathological lung changes while the group of rats 
ventilated on 30/0 and 30/10 had perivascular oedema but no alveolar oedema. 
Similarly, rats ventilated on 45/10 had no alveolar oedema and survived (Webb and 
Tierney, 1974). On the contrary, rats ventilated with higher pressures of 45/0 cmH2O 
had alveolar and perivascular oedema, severe hypoxemia, and decreased compliance 
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and died within one hour concluding that that interstitial perivascular oedema 
develops from ventilation with high tidal volumes generated by high distending 
pressures (Webb and Tierney, 1974).  
Several investigators questioned whether VILI was caused by the ventilatory 
pressures per se (i.e. barotrauma), or the resultant ventilatory volumes (i.e. volume 
trauma) (Dreyfuss and Saumon, 1993, Hernandez et al., 1989, Carlton et al., 1990, 
Dreyfuss et al., 1988). Hernandez and coworkers (Hernandez et al., 1989) addressed 
this question by comparing the effect of ventilation with 15, 30, or 45 cm H2O PIP 
on normal rabbits, rabbits encased in plaster casts to limit chest excursions, and 
excised rabbit lungs. No significant changes in capillary filtration coefficient (Kfc) 
or any signs of macroscopic lung injury were found in the rabbits encased in plaster. 
However, significant increases in Kfc were found in the other two groups (i.e. 
normal rabbits or ex vivo lungs). Therefore, they concluded that it was the large lung 
volumes (volutrauma), rather than the high airway pressures, which produced lung 
injury. A similar conclusion was reached by Dreyfuss et al., based on their findings 
of pulmonary oedema when rats were ventilated with either high tidal volumes and 
high airway pressures (high pressure conventional mechanical ventilation) or high 
tidal volumes and low airway pressures (negative pressure ventilation). In contrast, 
no pulmonary oedema was found with normal tidal volume ventilation at high 
airway pressures (positive pressure ventilation with thoraco-abdominal strapping) 






Whilst pressure and volume are inextricably linked, over expansion of lung 
parenchyma, rather than the absolute pressure, leads to lung injury (Dreyfuss and 
Saumon, 1992). The importance of volutrauma has been demonstrated in animal 
models. Young rabbits were exposed to peak inspiratory pressures (PIP) of 15, 30, 
and 45 cmH2O, in isolated lung preparations, intact rabbits, and rabbits in which the 
chest and abdomen were encased in plaster of Paris, limiting expansion. The lungs of 
the restricted expansion rabbits appeared macroscopically normal, and measurements 
of capillary permeability, increased in lung injury, remained static at each of the 
pressure intervals. In contrast, the lungs from uncasted rabbits showed progressive 
macroscopic damage as the pressure to which they were exposed increased, with 
increasing capillary permeability. The isolated lung preparations, with no restriction 
to expansion, were worst affected (Hernandez et al., 1989). This study demonstrates 
that volutrauma was more important than the absolute pressure applied in provoking 
this aspect of lung injury. This is particularly significant in premature neonates, 
whose compliant chest walls offer little protection against over-distension. 
Another animal study has shown that even a small number of large inflations soon 
after birth can adversely affect surfactant-deficient lungs (Bjorklund et al., 1997). In 
this study of new born lambs, one lamb of each of five pairs was randomly assigned 
to receive six large manual inflations ("bagging") after preterm delivery and before 
starting MV and receiving artificial surfactant. At four hours, the bagged animals 
compared with controls had lower inspiratory capacity and maximal deflation, were 
more difficult to ventilate, and had less well expanded alveoli and more widespread 
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lung injury on histologic examination. Injury caused by mechanical ventilation 
primarily is due to large tidal volumes (volutrauma) that over distended airways and 
airspaces, rather than increased airway pressures (Hernandez et al., 1989, Carlton et 




Atelectorauma results from regionally or totally reduced lung parenchyma 
expansion. Pulmonary injury is associated with alveolar instability: the successive 
collapsing and reopening of the alveolar walls cause the lysis of the structural 
elements that compose the lung interstitium, triggering local and systemic 
inflammation. Experimental models of surfactant deficiency showed that low-
volume MV induces cytokine release and initiates the inflammatory cascade, which 
also occurs in volutrauma (Froese et al., 1993). Studies performed during 
conventional MV of surfactant-depleted lungs with various levels of Peak end 
expiratory pressure (PEEP) provide support to the concept that the repeated opening 
and closing of terminal units causes additional injury (Sandhar et al., 1988, 
Muscedere et al., 1994). Muscedere et al. ventilated isolated, nonperfused, lavaged 
rat lungs at different end-expiratory pressures above and below the inflection point 
(Pinf) of the inspiratory pressure-volume curve. In the group ventilated with PEEP 
below Pinf, compliance fell dramatically after ventilation, and lung injury assessed 
morphologically was significantly greater (Muscedere et al., 1994). Another benefit 
of setting PEEP above this inflection point is that it usually results in a very abrupt 
decrease in shunt fractions and increase in PaO2 (Falke et al., 1972). It seems likely 
that unstable lung units may be damaged by repeated opening and closing during 
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tidal ventilation. PEEP may prevent diffuse alveolar damage during prolonged 
ventilation at high lung volume by stabilising distal units. This may explain in part 
the preservation of alveolar epithelium integrity and the decrease in oedema during 
high tidal volume mechanical ventilation in the presence of PEEP in a ventilated rat 
model (Dreyfuss et al., 1988), and minimisation of injury to ventilated surfactant-
deficient rabbit lungs by recruiting lung volumes and then maintaining a higher than 
normal FRC by high frequency oscillatory ventilation (McCulloch et al., 1988). 
Keeping end-expiratory lung volumes (EELV) high enough to prevent atelectasis, 
and using small tidal volumes to prevent over distension improved surfactant 
efficacy in premature rabbits (Gattinoni et al., 1987). Therefore, the lung apparently 
also has a low volume injury zone (Jobe and Ikegami, 1998). If both high and low 
volume lung injury concepts are clinically relevant, the logical inference is that MV 
of acutely injured lungs should be placed on the linear portion of the pressure-
volume curve (Dreyfuss and Saumon, 1994), above the lower inflection point but 
below the upper inflection (or ‘deflection’ point). This linear portion may be very 
short. In such case, a tidal volume (Vt) that would not be deleterious in normal lungs 
may lead to excessive end-inspiratory volume when the PEEP is set high enough to 






Numerous studies over the past twenty years have demonstrated that there can be 
release of various mediators into the lung, pulmonary recruitment of leukocytes, and 
local initiation of inflammatory processes. This biological response to mechanical 
forces has been called biotrauma (Tremblay and Slutsky, 1998). The biotrauma 
hypothesis postulates that the circulating mediators can cause local lung injury, and 
if they translocate into the systemic circulation, they may lead to distal organ 
dysfunction and death (Slutsky and Tremblay, 1998). 
Tremblay et al (Tremblay et al., 1997) found that isolated non-perfused rat lungs 
ventilated for two hours with large tidal volumes without PEEP had large increases 
in lavage concentrations of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, 
and macrophage inflammatory peptide 2. High Vt ventilation also increased 
expression of c-fos mRNA, a transcription factor important in the early stress 
response (Tremblay et al., 1997). 
The potential for ventilation-induced inflammation in humans was examined in 
forty-four patients with ARDS who were randomised to receive traditional or lung-
protective ventilation (Ranieri et al., 1999). Broncho-alevolar lavage (BAL) and 
plasma concentrations of several proinflammatory cytokines were lower in patients 
receiving protective ventilation, as were other indices of plasma and alveolar fluid 




Inflammation is a process that is a vital response to injury that needs to be triggered 
to bring about recruitment of blood leucocytes, activation of tissue macrophages, and 
production of a series of mediators. The inflammatory response to injury may 
include activation of macrophages that generate ‘early response cytokines’ like TNF-
ɑ and IL-1. These cytokines stimulate vascular endothelial cells to express vascular 
adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1), and E-
selectin. Blood neutrophils adhere to endothelial cells and transmigrate into the 
interstitial and alveolar compartments (Ward and Lentsch, 1999). The entry of 
neutrophils into the alveolar compartment together with tissue-activated 
macrophages sets the stage for injury of both lung cells and matrix glycoproteins 
(e.g., collagens, elastin). Injury is related to generation of oxidants by phagocytic 
cells and the release of proteases. The activation of NF-ⱪB in phagocytic cells is 
central to the generation of inflammatory mediators. NF- ⱪB has the ability to bind 
with promoter sequence in DNA and to inaugurate transcription (generation of 
messenger RNA) for many inflammatory peptides. The NF- ⱪB is held in check by 
inhibitors, which bind to the NF-ⱪB complex and prevent its entry into the nucleus 
(translocation) and subsequent binding to DNA. In the rat model of immune 
complex-induced alveolitis, several interleukins were found to have a strong anti-
inflammatory response, with IL-10=IL-13>IL-4>IL-6>IL-12 (Ward and Lentsch, 
1999). 
MV provokes the release of cytokines, both pro-inflammatory (IL-1, IL-6, IL-8, 
TNF-α) and anti-inflammatory (IL-10), and other mediators from the cells. In vitro 
studies suggest that this release is caused by mechanical stretch to the tissue, leading 
both to disruption of the contact between individual cells and also to transduction of 
the forces intracellularly via the cytoskeleton (Halbertsma et al., 2005). The pro-
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inflammatory response, increased in preterm neonates due to reduced anti-
inflammatory cytokine release (Oei et al., 2002), attracts neutrophils and other 
inflammatory cells to the airways, and also increases vascular permeability (Munshi 
et al., 1997, Groneck et al., 1994). Surfactant dysfunction, either due to a direct 
cytokine effect or due to increased alveolar capillary leak of proteins, increases the 
propensity for lung damage. It has been shown that preterm neonates who go on to 
develop BPD have higher levels of inflammatory cytokines and that these persist 
longer than those infants who do not develop BPD (Jonsson et al., 1997, Arnon et 
al., 1993, Tullus et al., 1996). This inflammatory cascade can induce apoptosis in 
pulmonary epithelial cells and is also implicated in the alteration of gene expression 
in injured lung tissue, both sustaining inflammatory responses and also modifying 
pathways involved in tissue repair and remodelling (Denervaud et al., 2015). Animal 
studies have demonstrated that lung injury induced by MV and associated with 
increased pro-inflammatory cytokine release leads to delayed alveolarisation and 
saccular wall fibrosis, similar to the histological changes found in neonates with 
BPD (Ratner et al., 2013, Coalson et al., 1999).  
The mechanical factors that lead to barotrauma, volutrauma and atelectrauma have 
been associated with inflammatory mediator-related injury which has been termed 
biotrauma.  MV promotes inflammation and direct damage to the lungs in premature 
infants.  For that reason, ventilator strategies which are least harmful are needed for 




1.4 Neonatal ventilation strategies 
 
Management strategies are aimed at protecting against lung injury and the 
development of BPD. As the pathogenesis of disease is multifactorial, diverse 
approaches have been adopted including both ventilation and medical strategies. 
Interestingly, both antenatal steroids and surfactant reduce rates of RDS and improve 
survival; however, neither has been shown to reduce incidence of BPD (Stoll et al., 
2015). It is important to determine the impact of different modes of ventilation on 
respiratory morbidity in order to optimise neonatal ventilation.  There are a number 
of modes of ventilation currently used to support prematurely born infants, including 
invasive and non-invasive methods.  
 
1.4.1 Invasive ventilation  
 
1.4.1.1 Volume targeted ventilation 
 
During VTV, a constant volume set by the practitioner is delivered to the infant 
regardless of changes in the infant's lung function. At least eighteen randomised or 
quasi-randomised trials have been undertaken comparing VTV to pressure-limited 
ventilation in prematurely born infants.  Meta-analysis (Peng et al., 2014) 
demonstrated that VTV was associated with a reduction in BPD (nine trials) and 
significant reductions in all IVH, grades 3–4 IVH, PVL and pneumothorax. In 
addition, the durations of MV and supplementary oxygen were shorter with VTV. 
55 
 
There was, however, no significant reduction in mortality and no long-term 
outcomes were reported. Difficulties in generalising the results of the meta-analysis 
are that different ventilators were used in the two arms of some trials and different 
volume targeting ventilators were used. A variety of mechanisms are used to achieve 
volume targeting and, as a consequence, there are differences in the airway pressure 
waveform and mean airway pressure at apparently the same Vt setting according to 
ventilator type (Sharma et al., 2007).  In addition, different levels of volume 
targeting used in the various trials and the VT level used significantly affects the 
WOB in infants with acute respiratory distress (Patel et al., 2010b) and in the 
recovery stage (Patel et al., 2009b).  
 
1.4.1.2  High-Frequency Oscillation  
 
During high-frequency oscillatory ventilation (HFOV), small tidal volumes are 
delivered at fast rates, usually in the range of 10 – 15 Hz. The performance of high 
frequency oscillators varies, but for all, the delivered volume is affected primarily by 
the oscillatory pressure and less by the frequency (Laubscher et al  1996).  Volume 
delivery, however, was reduced as frequency was increased (Laubscher et al  1996).  
Randomised clinical trials have demonstrated that HFOV have potential to reduce 
risk of BPD (Sun et al., 2014, Henderson-Smart et al., 2007); however, a Cochrane 
review of elective HFOV revealed only a small reduction in the incidence of chronic 
lung disease with notable inconsistency across the nineteen studies included (Cools 
et al., 2015). As many infants require more sedation with high frequency ventilation 
(HFV), prophylactic use of HFV remains controversial. 
56 
 
In the United Kingdom Oscillation Study (UKOS) (Johnson et al., 2002), 797 infants 
born prior to 29 weeks of gestation from 25 centres, were randomised uniquely 
within an hour of birth to HFOV or conventional ventilation (Johnson et al., 2002); 
no significant differences in short-term outcomes were demonstrated. There were 
also no significant differences in lung function results at one year of age (Thomas et 
al., 2004), but the results were only from a subset who lived close to the London 
centre and small airway function was only assessed by measurement of gas trapping. 
In another study (Hofhuis et al., 2002) demonstrated small airway function, as 
assessed by maximal flow at functional residual capacity (V′ max FRC) at 12 months 
corrected, was significantly better in infants who had been supported by HFOV 
rather than CMV. Those results (Hofhuis et al., 2002) were not from a randomised 
trial, but suggested that HFOV might preserve small airway function. That 
hypothesis was proven by an assessment of  320 “UKOS” children  when aged 11 to 
14 years, which demonstrated significant differences in small airway function in 




1.4.1.3  Patient triggered ventilation (PTV) 
 
1.4.1.3.1 Assist control and synchronised intermittent ventilation (AC and SIV)  
 
PTV was introduced into neonatal intensive care in the 1980s, initially as 
assist/control (A/C, inflations triggered by every spontaneous breath that exceeded 
the critical trigger threshold) and synchronised intermittent mandatory ventilation 
(SIMV), only the preset number of inflations is triggered regardless of the infant’s 
spontaneous respiratory rate). It was hoped that these ventilation modes would be 
more likely to promote synchrony between the infant and ventilator inflations and 
hence reduce air leaks and BPD. The recent Cochrane review (Greenough et al., 
2016) of randomised trials comparing AC/SIMV to pressure limited ventilation 
(PLV) demonstrated that ACV/SIMV compared to CMV was associated with a 
shorter duration of ventilation (mean difference (MD) 38.3 hours, 95% CI − 53.90 to 
−22.69). SIMV or SIMV + Pressure Support (PS) was associated with a greater risk 
of moderate/severe BPD compared to HFO (Relative Risk (RR) 1.33, 95% CI 1.07 
to 1.65) and a longer duration of mechanical ventilation compared to HFO (MD 1.89 
days, 95% CI 1.04 to 2.74). ACV compared to SIMV was associated with a trend to 
a shorter duration of weaning (MD − 42.38 hours, 95% CI −94.35 to 9.60). Neither 





1.4.1.3.2 Pressure support ventilation (PSV)  
 
During pressure support ventilation (PSV), the infant's inspiratory efforts determine 
both the initiation and termination of ventilator inflation. Ventilator inflation is 
terminated when the infant's inspiratory flow declines to a predefined level, which 
varies according to the type of ventilator.  A randomised trial (Reyes et al., 2006) 
showed that the use of PSV in addition to SIMV during the first week after birth 
facilitated weaning in infants of birth weight  ≤1000 g compared to SIMV alone. 
This was associated with a shorter oxygen dependency in infants of BW 700–1000 g. 
The likely benefits were explained by the results of a crossover study (Patel et al., 
2009a), where one hour  periods of SIMV and SIMV with pressure support were 
compared (n=20 infants, mean GA of 31 weeks). They found that the addition of 
pressure support to SIMV reduce the WOB in infants being weaned from the 
ventilator. The likely explanation for the success of PSV with SIMV versus SIMV 
alone is that, in the former ventilator strategy, all the infant's breaths are supported 




1.4.1.3.3 Proportional assist ventilation (PAV) 
 
During proportional assist ventilation (PAV), the applied pressure is servo 
controlled, based on continuous input from the infant’s breathing throughout each 
spontaneous breath. In addition, the ventilator can provide inflation pressure in phase 
with the Vt change in order to reduce the compliance load (i.e. the load due to the 
stiffness of infant’s lungs) and in phase with the flow change to reduce the resistance 
load (i.e. the load due to airflow obstruction), termed elastic and resistive unloading, 
respectively (Schulze, 2002). Very prematurely born infants developing or with 
established BPD will have stiff lungs (that is non-compliant) despite a very 
compliant chest wall, so may be particularly likely to benefit from elastic unloading.  
PAV, however, has only been assessed in neonates in a few studies. In prematurely 
born infants with acute respiratory disease, PAV was associated with maintenance of 
gas exchange with lower transpulmonary pressure swings compared to continuous 
mandatory ventilation (CMV) and ACV in a crossover study (Schulze et al., 1999). 
In evolving CLD in prematurely born infants, PAV was shown to provide 
satisfactory gas exchange at lower mean airway pressures compared to SIMV and 
ACV in a crossover study (Schulze et al., 2007), but PAV was demonstrated to 
reduce TAA and chest wall distortion in preterm infants (Musante et al., 2001). 
In a crossover study, infants with evolving or established BPD supported on PAV 
compared ACV had better oxygenation indices, a lower WOB and better respiratory 
muscle strength. The infants, however, were only studied on each ventilator mode 
for one hour (Bhat et al., 2015). The longest infants have been reported to be studied 
on PAV was four hours (Schulze et al., 2007), but during that study, only changes in 
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pulse oximetry results were assessed. During PAV, a trigger delay of 60 
milliseconds was demonstrated using an in vitro model (Patel et al., 2010a); hence, it 
is important to assess blood gases over a longer period than previously studied.  
 
1.4.1.3.4 Neurally adjusted ventilatory assist (NAVA)  
 
In 1987 Daubenspeck et al. described a new technique to evaluate the diaphragmatic 
EMG using an array of seven sequential electrode pairs on an oesophageal catheter 
(Daubenspeck et al., 1989). In the 1990’s Sinderby and Beck expanded this concept 
with the introduction of embedded electrodes in a nasogastric tube that detected a 
reliable diaphragmatic EMG signal. The signal reflected the patient’s neural 
respiratory drive in real time, and minimised artefacts (Sinderby, 2002, Beck et al., 
1998, Beck et al., 1995). The technology was integrated into a commercially 
available mechanical ventilator (Servo-I and Servo-N; Maquet, Solna, Sweden) that 
converted the electrical activity into a synchronised breath known as NAVA 
(Sinderby, 2002, Beck et al., 2015). 
NAVA is a mode of ventilation where the patient’s neural respiratory drive controls 
the timing and amount of assist provided (Sinderby et al., 1999, Sinderby C, 2012). 
The neural respiratory drive is interpreted from the diaphragm electrical activity 
(Edi), measured with small sensors on the patient’s Edi catheter at the level of the 
gastroesophageal junction.  Measuring the Edi in the oesophagus removes potential 
contamination from changes in lung volume, body position, intra-abdominal 
pressure, postural and expiratory muscles, the subcutaneous layers, and applied 
PEEP (Beck et al., 1998, Beck et al., 1995, Sinderby et al., 1999, Barwing et al., 
2011, Barwing et al., 2009). Signal integrity also does not seem to be influenced 
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when receiving bolus versus continuous nasogastric feeds (Ng E, 2010) or with milk 
influx during oral feeding (Stein et al., 2012). Edi has been shown to correlate with 
transdiaphragmatic pressure (Beck et al., 1998, Beck et al., 2001, Fauroux et al., 
2003) and with the pressure generated by the respiratory muscles and inspiratory 
effort (Bellani et al., 2013).   
There are few studies of NAVA and they address short-term outcomes, but available 
data are encouraging. In a retrospective analysis of the results of fifty-two neonates 
changed to NAVA from conventional ventilation, peak inflation pressures and 
supplementary oxygen levels were lower and the partial pressure of carbon dioxide 
improved during NAVA (Stein and Howard, 2012). Those results were subsequently 
confirmed in a prospective study of five infants each exposed to four hourly cycles 
of pressure controlled ventilation and NAVA, despite lower peak inflation pressures 
the partial pressure of carbon dioxide was lower during NAVA (Stein et al., 2013a). 
In a four hour crossover comparison between NAVA and SIMV with PS, in twenty-
six preterm infants, the WOB was lower on NAVA and blood gases were maintained 
despite lower peak pressures (Lee et al., 2012). NAVA compared to pressure 
regulated-volume control has also been associated with less asynchrony and need for 
sedation (Longhini et al., 2015).   
Infants with evolving or established BPD have a high resistance which means flow 
triggering can be challenging. In addition, the severity of their lung function 
abnormalities likely means that supporting each breath throughout the inspiratory 
cycle ie with a small trigger delay would be advantageous. This thesis will test the 
hypothesis that NAVA compared to ACV would result in a lower oxygenation index 




1.4.2 Non-invasive respiratory support 
 
Significant efforts have been made to move away from use of invasive ventilation 
over the past two decades (Stoll et al., 2015). In a secondary analysis from the 
Caffeine for Apnea of Prematurity (CAP) trial, higher rates of BPD in infants who 
were intubated at birth compared with those who were stabilised with non-invasive 
CPAP were found (DeMauro et al., 2011). A recent meta-analysis of four RCTs with 
a total of 2782 very preterm infants compared early use of CPAP to intubation and 
MV (Morley et al., 2008, Network et al., 2010b, Sandri et al., 2010, Dunn et al., 
2011, Schmolzer et al., 2013). BPD rates were only modestly reduced with early 
CPAP (32.4% vs.34.0%), and the results failed to meet statistical significance (RR, 
0.91; 95% CI, 0.82 – 1.01) (Schmolzer et al., 2013). Use of alternative non-invasive 
modalities including non-invasive positive pressure ventilation (NIPPV), bi-level 
nasal CPAP (biPAP) and HHFNC is also increasing with some evidence to suggest 
these modes may also be effective in managing neonatal respiratory disease 
(Hutchison and Bignall, 2008, Kugelman et al., 2007, Yoder et al., 2013). Studies 
have identified that an early attempt at extubation alone may decrease the risk of 
BPD, regardless of need for reintubation or duration of ventilation (Jensen et al., 
2015, Robbins et al., 2015).  
The optimal approach, impact on BPD and long-term outcomes with use of non-
invasive ventilation (NIV) remain to be defined. Studies above suggest a need for 




1.4.2.1 Continuous positive airway pressure (CPAP) 
 
CPAP has been used since the 1970’s as a modality to prevent alveolar collapse by 
maintaining mean airway pressure (Gregory et al., 1971). A survey of eight tertiary 
neonatal centres  in the United States of America (USA) (Avery et al., 1987) 
demonstrated the centre which used CPAP as initial respiratory support had the 
lowest rate of BPD with similar survival rates; the other centres used intubation and 
ventilation as their initial ventilatory mode. Other observational studies highlighted 
that use of early CPAP was associated with significantly less need for intubation and 
ventilation (Aly et al., 2004, Miksch et al., 2008, Narendran et al., 2003) and BPD 
(Aly et al., 2004, Miksch et al., 2008, Ammari et al., 2005, Birenbaum et al., 2009). 
There have subsequently been randomised trials which have yielded differing results.  
The COIN trial (Continuous Positive Airway Pressure or Intubation at Birth) 
(Morely et al., 2008) showed that the use of early CPAP in the delivery suite in very 
preterm infants (25 – 28 weeks) compared to intubation and ventilation was 
associated with  lower risk of the combined outcome of death or need for oxygen 
therapy at 28 days, but there was no significant difference in oxygen dependency at 
36 weeks post menstrual age. The trial however highlighted that the CPAP group 
had a higher incidence of pneumothorax, which might relate to the CPAP pressure of 
8 cm H2O or the lower use of prophylactic surfactant. In the SUPPORT trial 
(intubation and early surfactant followed by CPAP versus early CPAP) (Finer et al., 
2010), there was no significant difference in the primary outcome of death or BPD, 
although there was higher postnatal steroid use in the intubation–surfactant group 
(13.2% vs. 7.2%, p < 0.001). The CPAP group required significantly less days of 
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mechanical ventilation (p = 0.03) and had a significantly higher rate of survival free 
of mechanical ventilation at seven days (RR 1.14, 95% CI, 1.03–1.25). A 
prospective follow up study to SUPPORT, the breathing outcomes study (Stevens et 
al., 2014), assessed respiratory morbidity at 6-month intervals from hospital 
discharge to 18 – 22 months corrected age. The study found that infants randomised 
to early CPAP rather than intubation and early surfactant had fewer episodes of 
wheezing without a cold, fewer respiratory illnesses diagnosed by a doctor, and 
fewer physician or emergency room visits for breathing problems. In the CURPAP 
trial (prophylactic surfactant followed by CPAP versus early CPAP) (Sandri et al., 
2010), no significant difference was found in the primary outcome, the need for MV 
in the first 5 days or in the secondary outcomes including death, BPD, air leaks, 
grades 3-4 IVH, sepsis, retinopathy of prematurity and pulmonary haemorrhage. A 
subsequent Randomised controlled trial (RCT) randomised 648 infants to one of 
three arms: initial management to prophylactic surfactant followed by a period of 
mechanical ventilation, prophylactic surfactant followed by rapid extubation to 
bubble CPAP or bubble CPAP and selective surfactant (Dunn et al., 2011). The 
study was terminated early because of declining recruitment. There were no 
significant differences between the groups with regard to mortality or other 
complications of prematurity (Dunn et al., 2011). A meta-analysis of four RCT’s, 
(Morely et al., 2008, Dunn et al., 2011, Network et al., 2010b, Sandri et al., 2010) 
comparing use of nCPAP to intubation in infants born at less than 32 weeks of 
gestation  demonstrated nCPAP was associated with a significant reduction in BPD 
or death (Schmolzer et al., 2013). Thus, early CPAP therapy for preterm infants 
compared to invasive ventilation has been demonstrated to be associated with less 




1.4.2.1.1 Methods of CPAP generation 
 
There are a number of methods of CPAP generation and delivery. Devices which 
generate CPAP can broadly be divided into two categories, continuous flow or 
variable flow devices. Continuous flow devices include conventional ventilators, jet 
ventilation systems and bubble CPAP. Conventional ventilators provide a constant 
flow of gas and the pressure is controlled by the exhalation valve. With a jet system, 
a small jet is produced either at the nostrils or in a prechamber in front of the nasal 
prongs. During bubble CPAP, a variable flow device, the pressure is set by 
immersing the expiratory limb of the CPAP device in an underwater chamber to a 
depth equal to the desired CPAP level. The gas flows through the system causing 
bubbling in the chamber; this causes variability in the mean CPAP pressure. Using a 
variable flow device, the CPAP level is dependent on the flow of gas. There have 
been few randomised trials comparing methods of CPAP generation, the results of 
those studies have suggested that variable-flow CPAP has advantages over 
ventilator-delivered CPAP being associated with lower duration of supplementary 
oxygen, length of stay (LOS) and WOB and greater stability of flow and tidal 
volume (Huckstadt et al., 2003, Pandit et al., 2001, Stefanescu et al., 2003). In 
subgroup analysis of infants ventilated for less than two weeks, bubble CPAP 
compared to variable-flow CPAP was associated with a significantly lower rate of 
extubation failure, as well as a significantly reduced duration of CPAP, but overall, 
there were no significant differences in the rates of successful extubation (Gupta et 




1.4.2.1.2 CPAP delivery 
 
Short binasal prongs and nasal masks are two of the most commonly used interfaces 
for delivering CPAP (Kieran et al., 2011). Other methods include a nasopharyngeal 
prong, an endotracheal tube and a helmet. In a short-term randomised crossover 
study, ‘helmet’ CPAP was found to be as effective as nasal CPAP with respect to 
oxygen requirement, oxygen saturation (SaO2), heart rate (HR), respiratory rate 
(RR), mean arterial blood pressure (MAP), and transcutaneous carbon dioxide. In 
addition, helmet CPAP use was associated with a significant increase in infant 
comfort assessed by the Neonatal Infant Pain Scale (Trevisanuto et al., 2005). There 
are, however, concerns that it may adversely affect cerebral blood flow (Zaramella et 
al., 2006) and it is associated with significantly higher noise levels than nasal CPAP 
(Trevisanuto et al., 2011). 
Short binasal prongs are associated with a lower WOB compared to nasopharyngeal 
prongs (De Paoli et al., 2002). The results of a meta-analysis highlighted that binasal 
prongs were more effective in preventing reintubation in prematurely born infants 
when compared to either single nasal or nasopharyngeal prongs (De Paoli et al., 
2008). Nasal injury has been described using short nasal prongs. In a randomised 
study which included eighty-nine very low-birthweight infants, no significant 
difference in the incidence of nasal injury was demonstrated between nasal prongs 
and nasal mask, but the incidence of nasal injury was significantly associated with 
CPAP duration (Yong et al., 2005). Continuous method of CPAP with nasal mask 




1.4.2.2  Heated Humidified High Flow Nasal Cannula (HHFNC) 
 
During humidified, high flow nasal cannula (HHFNC), heated and humidified gas is 
delivered at flow rates between 2 – 8 L/min via nasal cannulae. It  has been 
suggested that  HHFNC may be effective by eliminating the dead space (Dysart et 
al., 2009), reducing the WOB (Saslow et al., 2006), improving lung compliance at 
higher flow rates (Saslow et al., 2006) and delivering some degree of continuous 
positive airway pressure (Dysart et al., 2009, Spence et al., 2007). There are, 
however, concerns about the  unpredictability of the positive airway pressures 
generated (Kubicka et al., 2008, Lampland et al., 2009, Finer and Mannino, 2009) 
and the possibility of increased risk of infection, particularly due to Ralstonia species 
(CDC, 2005) and gram-negative organisms (Shoemaker et al., 2007) resulting from 
contaminated humidifier cartridges in the Vapotherm 2000i device in 2005 (Jhung et 
al., 2007). Following the introduction of stricter infection control guidance by the 
manufacturer, there have been no further infection concerns since. Nevertheless, the 
technique has become popular, HHFNC has gained popularity in many countries 
(Ojha et al., 2013, Hochwald O, 2010, Hough et al., 2012, Manley et al., 2013, 
Roehr et al., 2007, Manley et al., 2012). Sixty three percent of units in Australia and 
New Zealand were reported to be using HHFNC in 2010 (Manley et al., 2012). A 
survey of fifty-seven level two or three neonatal units in the UK reported in 2013 
that HHFNC was used in 77% of units (Ojha et al., 2013). In addition, infants were 
perceived to be more comfortable and more easily handled on HHFNC compared to 




1.4.2.2.1 Distending pressures generated by HHFNC  
 
The distending pressure delivered by HHFNC is dependent on prong size. There 
have been several attempts to produce a formula to calculate the pressure generation 
during HHFNC at different flow rates on the basis of infant weight, but inconsistent 
results have been produced (Dysart et al., 2009, Sreenan et al., 2001). Airway 
pressure increases with the nasal prong to nares ratio (Sivieri et al., 2013). In an in 
vitro system (Lampland et al., 2009), and in eighteen infants (Wilkinson et al., 
2008), the pressure increased with increased flow (Lampland et al., 2009). In 15 
patients with RDS, the presence of a leak as small as 30% reduced the pressure to 
less than 3 cm H2O (Lampland et al., 2009). Among infants with a postmenstrual age 
of between 29 and 44 weeks, and a birth weight of 835–3735 g, no pressure was 
generated when the infants’ mouths were open, regardless of whether flow rates of 
up to 5 L/min were used (Kubicka et al., 2008). When the infants’ mouths were 
closed, the oral cavity pressure was related to both flow rate and weight. For the 
subgroup of infants with birth weights ≤1500 g, there was a linear relationship 
between flow rate and oral cavity pressure (Kubicka et al., 2008). In a model, small, 
medium and large nares were simulated by holes drilled in a plastic fixture, which 
was connected to a lung simulator that simulated spontaneous breathing (Volsko et 
al., 2011). Nasal cannulae were inserted in the nares of the model, ensuring that the 
occlusion of the nares did not exceed 50%. Flow was adjusted from 2 to 6 L/min in 1 
L/min increments. Not surprisingly, the greatest effects on Vt and pressure change as 
flow was increased, occurred with the smallest cannula. Another study (Collins et al., 
2013b), compared pharyngeal pressures using two commonly used HHFNC devices, 
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the Fisher & Paykel Healthcare HHFNC (Auckland, New Zealand) and the 
Vapotherm 2000 (Vapotherm Inc., Stevensville, MD,USA), in nine infants at flow 
rates of 2 – 8 L/min. There was no difference in pharyngeal pressures recorded 
between devices at flow rates of 2 – 6 L/min. At flow rates of 7 L/min, the 
Vapotherm delivered a mean pharyngeal pressure of 4.7, with a standard deviation 
(SD) of 2.2 cm H2O, compared with a mean of 4.23 (SD 2.2) cm H2O by the Fisher 
& Paykel device (p = 0.04). At a flow of 8 L/min, the mean pharyngeal pressure via 
the Vapotherm was 4.9 (SD 2.2) cm H2O, compared with 4.1 (SD 2.3) cm H2O with 
the Fisher & Paykel device (p = 0.05). Whether such differences are clinically 
important remains to be determined and further studies are required to assess the 
relationship between flow and pressure in a variety of patient groups. 
Flow rates needed to generate significant positive airway pressure remain unclear.  
Lampland et al. (2009) found that end-expiratory oesophageal pressure increased 
linearly with flow rate (1-6L/min), however there was large inter-patient and intra-
patient variability, therefore delivered pressure for a given flow rate could not be 
predicted. Lavizarri et al. (2014) randomised twenty preterm infants with mild-
moderate respiratory distress to receive CPAP (at 2, 4 or 6cm H2O) and HHFNC (at 
2, 4 or 6L/min). Retropharyngeal pressure was measured between periods of CPAP 
and HHFNC. It was found that the retropharyngeal pressures achieved during 
HHFNC were very variable. Retropharyngeal pressures of 2cm H2O was achieved in 
four infants with 2 L/min and in eleven infants with 4L/min, whilst pressures of 4cm 
H2O was reached in four infants with 4L/min and in eleven infants with 6L/min. 
Pressures of 6cm H2O were only obtained in five of the twenty infants supported 
with HHFNC, whereas 6cm H2O of CPAP achieved pressures of 6cm H2O in all 
twenty infants. This study highlights the variability in airway pressures achieved 
70 
 
during HHFNC, and thus confirms the unpredictability of the pressures generated by 
HHFNC.  
 
1.4.2.2.2 Work of breathing (WOB) and HHFNC  
 
In a crossover study (Saslow et al., 2006), 18 infants with a birth weight <2 kg and a 
mean gestational age (GA) of 28 weeks were randomised to 6 cm H2O nCPAP or 
HHFNC delivered at 3, 4 and 5 L/min. No significant differences in the WOB on the 
two respiratory support modes were reported. Measurements of tidal oesophageal 
pressure were used to approximate pleural pressures using an oesophageal balloon 
catheter (Viasys Healthcare Inc., Palm Springs, CA). In another study (de Jongh et 
al., 2014), the WOB was compared in a crossover study involving twenty infants 
(mean GA 28 weeks and BW 1.5 kg) at two levels of nCPAP settings 5 and 6 cm 
H2O and two levels of HFNC settings 3 and 5 L/min. The WOB was assessed using 
respiratory inductive plethysmography (RIP). They found that infants on nCPAP had 
significant greater chest and abdomen synchrony on CPAP compared with HHFNC, 
but there was overlap of the confidence intervals; hence, the authors suggested the 
results were unlikely to be of clinical significance. In a third study (Lavizzari et al., 
2014), twenty infants with mild or moderate RDS less than 96 hour old were studied, 
no significant differences were found in the WOB and lung mechanics during 
periods of support on nasal CPAP (nCPAP) (2, 4 cm H2O) and HHFNC (2, 4 L/min). 
Tidal volume by RIP, pleural pressure estimated by oesophageal pressure, and gas 
exchange were evaluated at each setting and used to compute breathing pattern 
parameters, lung mechanics and WOB.  
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None of the above studies looked into WOB of infants with evolving or established 
BPD, and hence the need for the study in the thesis comparing WOB between 
HHFNC and CPAP in evolving or established BPD.  
 
1.4.2.2.3 The efficacy of HHFNC compared to CPAP 
Four studies, including three post-extubation studies, were considered in a Cochrane 
review, which concluded that, post-extubation, HHFNC may be associated with a 
higher rate of intubation than nCPAP. In addition, the review highlighted that there 
was insufficient evidence to establish the safety or efficacy of HHFNC as a form of 
respiratory support for prematurely born infants ie infants born less than twenty eight 
weeks gestation (Wilkinson et al., 2011). In a multicentre trial, infants randomised to 
HHFNC compared with those randomised to nCPAP did not differ significantly with 
regard to the primary outcome, which was treatment failure within seven days. If 
HHFNC failed, the infants could then be transferred to nCPAP and if nCPAP failed, 
infants were reintubated. Almost half of the infants not successfully supported by 
HHFNC were subsequently successfully treated with CPAP without reintubation. 
The incidence of nasal trauma was lower in the HHFNC group than in the CPAP 
group (p=0.01). There were no significant differences in the rates of death before 
discharge, need for oxygen supplementation at 36 weeks of PMA, pneumothorax, 
PDA, requiring treatment, NEC, retinopathy of prematurity (ROP) or intraventricular 
haemorrhage (IVH) (Manley et al., 2013).  
In a randomised trial of 432 infants of 28–42 weeks of GA, no significant difference 
was seen in early (<72 h) extubation failure between infants on HHFNC (10.8%) 
compared with nCPAP (8.2%) (Yoder et al., 2013). There was also no significant 
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difference in the subsequent need for intubation or in adverse outcomes including air 
leak between the two groups. Infants remained on HHFNC longer than on nCPAP 
(median 4 versus 2 days, p = 0.01). There were no significant differences with regard 
to days on supplemental oxygen (median: 10 versus 8 days) or the incidence of BPD 
(20% versus 16%).  
Collins et al. (Collins et al., 2013a) randomly assigned 132 infants less than 32 
weeks of gestational age to receive either HHFNC or nCPAP post-extubation. The 
primary outcome of extubation failure in the subsequent seven days was defined as 
at least one of the following: apnoea (respiratory pause more than 20 seconds), more 
than six episodes in 6 hours or one requiring intermittent positive pressure 
ventilation, acidosis, pH<7.25 and arterial carbon dioxide levels more than 66 
mmHg and more than a 15% sustained increase in the inspired oxygen concentration. 
No significant differences were found in the primary outcome or in the number of 
infants reintubated in the first week. The mean nasal trauma score, however, was 
lower in the HHFNC group (3.1 versus 7.4, p < 0.001).  
 
1.5  Outcome measures 
 
This thesis will utilise physiological measurements and oxygenation indices as 
outcome measures. The physiological outcome measures will be work of breathing 
(WOB), thoraco-abdominal asynchrony (TAA) and assessment of oxygenation 
indices (OI). In addition, time to achieve full oral feeds will be determined for the 




1.5.1 Assessment of work of breathing 
 
Infants with BPD may be compromised by several factors, which include 
respiratory limitations and increased energy needs.  The work of breathing 
gives an indication as to how much energy the infant is expending to inhale and 
exhale (Cabello and Mancebo, 2006), and thus a low WOB suggests lower 
respiratory muscle work. The work of the respiratory muscles may be assessed 
by either calculating the mechanical work or by evaluating the oxygen cost of 
breathing (Milic-Emili et al., 1999). A method of quantifying the effort 
expended by the respiratory muscles is the pressure time product (PTP) 
(Cabello and Mancebo, 2006).  
Work in a two-dimensional system is equal to the force applied to an object 
multiplied by the distance the object travels. That is,  
Work = force × distance, or W = F × D 
However, in the three-dimensions that apply in the respiratory system, work 
now becomes the pressure applied to yield a change in the volume of the 
system, or  
W = P × V =  × dv   
in which  is the integral of the pressure across the respiratory system, as a 





1.5.2 Assessment of the diaphragmatic pressure time product 
 
Pressure time product (PTP) is defined as the pressure developed by the 
respiratory muscles integrated to the time taken for the contraction (Cabello 
and Mancebo, 2006). The pressure time product of the diaphragm (PTPdi) can 
be calculated from the time integral of the transdiaphragmatic pressure (Pdi) 
(Brochard, 1991), where Pdi is the difference between pressures in the thoracic 
(pleural) and abdominal compartments, which are represented by the 
oesophageal (Poes) and gastric (Pgas) pressures respectively. In this thesis 
PTPdi will be used as a measure of WOB.  
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1.5.3 Thoracoabdominal asynchrony  
 
Asynchrony between the motion of the chest wall (ribcage) and abdomen occurs in 
respiratory distress  (Hammer and Newth, 2009). Asynchrony occurs frequently in 
prematurely born infants as they have a predominantly cartilaginous ribcage that is 
highly compliant (Gerhardt and Bancalari, 1980). In infants with BPD, the degree of 
asynchrony has been shown to be directly proportional to airways resistance and 
inversely proportional to lung compliance (Allen et al., 1991). The increased 
negative pleural pressure generated during inspiration in infants with a high airways 
resistance is transmitted to the highly compliant chest wall, uncoupling rib cage and 
abdominal wall motion (Allen et al., 1990). The degree of asynchrony between the 
ribcage and abdominal motion is related to the inspiratory load which in turn may 
lead to fatigue (Tobin et al., 1987). 
Thoracoabdominal motion may be assessed using a Respiratory inductance 
plethysmography (RIP) to map the magnitude and duration of both ribcage and 
abdominal motion. The two signals are mapped on an XY plot to form a Lissajous 
figure from which a phase angle can be calculated (Figure 1-4, 1-5 and 1-6). Once 
the Lissajous figures are constructed, an index of asynchrony was then calculated as 
described Allen et al (Allen et al., 1990), by dividing the width of the loop at mid 
ribcage excursion (m) by the width at the extremes of abdominal 90 excursion (s). 
Degrees of motion (φ) was calculated from the radian, where sin φ (in radians) = 
m/s, where φ is < 90 and where φ is  > 180, then φ =180 –sin (m/s) (Allen et al., 
1990, Mayer et al., 2003). This is done using the Excel spreadsheet (Microsoft 
corporation, USA). Completely synchronous motion has a phase angle of zero 
degrees (figure 1-4) and paradoxical motion an angle of 180 degrees (figure 1-5) 
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(Allen et al., 1990) . In this thesis, RIP will be used to measure TAA due to the 
relative ease of interpretation and non-invasive nature.  
 
Figure 1-4: Complete synchronous motion of the rib cage and the abdomen 
 
 






Figure 1-6: Lissajous figures demonstrating various degrees of asynchronous 
motion of the rib cage and the abdomen. 
Figures 1-4 to 1-6: Reprinted with permission of the American Thoracic Society. 




1.5.4 Blood gases 
 
 
The oxygenation index will be used to assess the intensity of ventilatory support 
required to maintain oxygenation. A lower OI is better. 
: 
Oxygen Index (OI) = 
FiO
2
 x MAP x 100 
--------------------- 





FiO2: Fraction of inspired oxygen in percentage 
MAP: Mean Airway Pressure (mmHg) 
PaO2:  Partial pressure of arterial oxygen (mmHg) 
 
 
Weaning of FiO2 in the clinical studies was done by the bed-side nurse to avoid any 













 PAV compared to ACV will improve oxygenation as assessed by the oxygen 
index (OI). 
 NAVA compared to ACV will improve oxygenation as assessed by the OI. 
 Current use of HHFNC will not have increased in view of the results of recent 
randomised trials.  












Overall aim is to undertake series of studies involving invasive and non-invasive 
ventilation using physiological measurements as outcomes in infants with evolving 
or established bronchopulmonary dysplasia (BPD), and to carry out a national 
survey. 
 To determine if PAV compared to ACV will improve oxygenation as assessed by 
the OI. 
 To determine if NAVA compared to ACV reduces the WOB and asynchrony 
with improvements in oxygenation. 
 To conduct a survey to evaluate current practice regarding the use of HHFNC in 
all United Kingdom neonatal units. 
 To determine in infants who are chronically CPAP dependent i.e. they are 
receiving CPAP two weeks after birth, whether HHFNC reduces the WOB and 































2.1 Overview of protocols and ethical approval  
 
2.1.1 Randomised crossover study comparing PAV with ACV 
 
Recruited infants were randomly assigned to receive either PAV or ACV. Each 
infant was exposed to each mode for four hours, at the end of which an arterial blood 
sample was obtained, the ventilator settings were noted and the OI was calculated. 
The infant was then switched over to receive the other mode. Mean respiratory rate 
(RR), tidal volume (Vt) and mean airway pressure (MAP) was calculated over the 
last five minutes of the four hour study period. All the infants had continuous oxygen 
saturation monitoring. The data were obtained from the nursing chart taken each 
hour and mean calculated.  
The South East London Research Ethics Committee approved the study (REC 
reference number: 07/H0808/147). Infants were entered into the study if their parents 
gave informed written consent. The study was undertaken at King’s College Hospital 




2.1.2 Randomised crossover study comparing NAVA with ACV 
 
A randomised crossover study comparing NAVA to ACV was undertaken in 
prematurely born infants. Infants were studied for one hour each on NAVA and 
ACV in random order. At the end of each hour the Edi Peak and Edi min, MAP and 
dynamic compliance (Cdyn) were measured and the oxygenation index (OI) 
calculated. In addition, the HR, RR and oxygen saturation were noted. Data obtained 
by the Edi catheter was downloaded from the ventilator into Excel via USB stick.  
The study was approved by the West Midlands - Solihull Research Ethics 
Committee (REC reference number: REC15/WH/0330). Infants were entered into 
the study if their parents gave informed written consent. The study was undertaken at 
King’s College Hospital NHS Foundation Trust, London.  
 
2.1.3 Survey to evaluate current practice regarding the use of HHFNC in all 
United Kingdom neonatal units. 
 
In 2015, clinicians in all UK neonatal units, identified from the National Neonatal 
Audit Programme (NNAP) Report, British Association of Perinatal Medicine 
(BAPM) directory and a departmental database from previous audits, were sent an 
email inviting them to complete an electronic web-based survey using Survey 
Monkey. Non-responders were sent email reminders and then contacted by 





2.1.4 Comparison of WOB between CPAP and HHFNC in infants with 
evolving BPD  
 
A randomised crossover study comparing the WOB between CPAP and HHFNC 
was undertaken in prematurely born infants with evolving BPD. Infants were studied 
on two consecutive days. On each study day infants received CPAP and HHFNC 
each for two hours, the order of which was randomised. The order in which the 
modes were delivered was reversed on the second day. The WOB was assessed by 
measuring the pressure time product of the diaphragm (PTPdi). PTPdi, TAA and 
SaO2 were assessed during the final five minutes of each two hour period and 
average values calculated.  
The study was approved by the London – Westminster Research Ethics Committee 
(REC reference number: REC 14/LO/0202). Infants were entered into the study if 
their parents gave informed written consent. The study was undertaken at King’s 








2.2.1  Blood gas analysis 
 
Measurement of blood pH, pCO2 and pO2 and the calculation of OI were performed 
using the blood gas equipment available on the NICU at King’s College Hospital 
(ABL 700 series, Radiometer, Copenhagen, Denmark). In the randomised crossover 
studies of PAV versus ACV 0.2 – 0.3 millilitres of blood was withdrawn from an 
infants’ indwelling arterial line, inserted by the clinical team for clinical reasons 
prior to commencing the study. For NAVA versus ACV study, capillary blood 
samples were taken via a heel prick. The blood gas machine was automatically 
calibrated four times in each 24-hour period. In addition, the blood gas analyser 
underwent a quality control (QC) check with the bioengineer at least once every 24 





2.2.2  Comparison of WOB between CPAP and HHFNC in infants with 
evolving BPD  
 
2.2.2.1  Measurement of airway flow and pressure 
 
Respiratory flow was measured using a pneumotachograph (F10L, GM Instruments, 
Kilwinning, Scotland) and associated differential pressure transducer (MP45 range 
+/- 2 cmH2O, Validyne, Northridge CA, USA). The pneumotachograph was 
calibrated prior to each study using a rotameter (10 L/min KDG Mobrey®, England).  
Airway pressure was measured using a differential pressure transducer (MP45 range 
+/-100 cmH2O, Validyne, Northridge CA, USA) attached to a side arm on the 
pneumotachograph via a fine bore catheter.  The flow and pressure signals from were 
amplified (CD 280, Validyne Northridge CA, USA) prior to acquisition.  
 
2.2.2.2 Linearity of the pneumotachograph 
 
The linearity of the pneumotachograph / transducer / amplifier / system was tested 
by passing air at known flows through the pneumotachograph and plotting the 
amplified electrical output against actual flow delivered by the rotameter.  The 










2.2.2.3 Linearity of the airway pressure transducer 
 
The linearity of the airway pressure transducer was tested using a digital pressure 
meter (C950315/IS, Comark Limited, Welwyn Garden City, UK). The transducer 
was connected to the pressure meter using a three way tap and pressures were 
applied using a hand held syringe in 10 cmH2O increments from -150 to 150 cmH2O. 
The linearity of the Comark pressure meter was tested against a water manometer 
(Figure 2-2).The applied pressures measured by the digital pressure meter were 
plotted against the corresponding amplified output voltage from the transducer 
converted to digital units by the acquisition system software. The transducer had a 
linear response over a range ± 150 cmH2O. The pressures measured and reported in 
this thesis lie within this range. 
 
 





2.2.2.4 Measurement of intrathoraic, intra-abdominal and transdiaphragmatic 
pressure 
 
Intrathoracic and intraabdominal pressures were obtained by measuring the pressures 
in the lower third of the oesophagus (Poes) and stomach (gastric pressure (Pgas)) 
respectively, using a dual pressure transducer tipped catheter (Gaeltec CTO - 2, 
Gaeltec Ltd, Isle of Sky, Scotland) and its associated amplifier (model type S7b/2, 
Gaeltec Ltd, Isle of Skye, Scotland). The catheter was 120 cm in length, and 
mounted with two miniature strain gauge transducers (5 x 2 mm). The gastric 
transducer was mounted at the tip of the catheter and the oesphageal transducer was 
mounted five cm proximal from the gastric transducer. The external diameter of the 
catheter was 2.1 mm. Prior to insertion, the catheter was lubricated with sterile 
aqueous gel (Aquagel, Williams Medical Supplies, Gwent, Wales, UK) and either 
inserted nasally or orally and advanced until the distal transducer was located in the 
stomach and the proximal transducer in the lower third of the oesophagus which was 
indicated by a positive deflection in Pgas and a negative deflection in Poes. Correct 
positioning of the Poes transducer was checked by comparing oesophageal to airway 
pressure during an occluded breath. Agreement between Poes oesophageal and 
mouth pressures within 90% and 110% (Beardsmore et al., 1980, Baydur et al., 
1982) indicated that the transducer was correctly located in the thoracic oesophagus 




2.2.2.5  Calibration 
 
To calibrate the pressure transducer-amplifier system, the catheter was placed inside 
an airtight calibration tube and the amplifier zeroed at ambient pressure. A known 
pressure was then applied to the catheter using the digital pressure meter and the gain 
of the amplifier was set to 50 cmH20/V. Prior to each study, the dual tipped pressure 
transducer catheter-amplifier-computer system was calibrated with a two point 
calibration. The lower, zero point being atmospheric pressure and the upper, either 
negative or positive pressure, applied using the calibration tube and measured using 
the digital pressure meter. The linearity of the dual tipped pressure transducer 
catheter-amplifier-computer system was tested as described above for the differential 
pressure transducer across the range ± 150cmH2O using the digital pressure meter. 
 
 








2.2.2.6   Frequency response 
 
The respiratory rate of a neonate is between 60 to 120 breaths per minute. The 
fundamental frequency (the first harmonic) is therefore 1-2 Hz. The first ten 
harmonics contribute to the pressure waveform. Ideally the frequency response of the 
measuring system should be at least ten times the frequency of the infant’s 
respiratory efforts, i.e. 20 Hz, to enable it to reproduce the first ten harmonics of the 
pressure wave without distortion. 
The frequency response was determined by creating a quasi-instantaneous change in 
pressure using  a ‘pop test’ in which an inflated balloon was fitted over the signal 
input site and then burst, producing an instantaneous negative step input to the 
system. The frequency response of the system (f3db) was calculated using the 
equation f3db =1/3 x Tr, where Tr (response time in seconds) is defined as the time 
taken for pressure to fall from 90% to 10% of the initial pressure (Figure2-5). 
The frequency response of each system used was determined using the pop test 
method, with the change in pressure against time recorded on a computer (MacBook, 
Apple Computer Corp, Cupertino, California, USA) using Chart software (Version 
5.0, ADInstruments Pty Ltd, Bella Vista, NSW Australia) with analogue-to-digital 





The frequency response of the airway pressure transducer system (consisting of the 
pressure transducer, connecting tubing, amplifier and computer) was determined by 
placing the tubing which connected the transducer to the pneumotachograph sideport 
inside an inflated balloon which was then burst. The response time was 8 
milliseconds (0.008s), giving a calculated frequency response of 41.6 Hz. 
The frequency response of the flow measurement system (consisting of the 
pneumotachograph, connecting tubing, pressure transducer for flow, amplifier and 
computer) was determined by attaching one end of the pneumotachograph to an 
inflated balloon. Partial occlusion of the other end of the pneumotachograph, 
allowed a constant background flow to be produced. Once flow through the 
pneumotachograph had been established at a constant rate, the balloon was burst 
resulting in an immediate fall in airflow to zero. The response time was 9 
milliseconds (0.009s), giving a calculated frequency response of 37 Hz. 
The frequency response of the oesophageal and gastric pressure transducing system 
(consisting of the dual microtransducer-tipped catheter, amplifier and computer) was 
tested by placing the catheter inside an inflated balloon which was then burst. The 
response time was 3.6 milliseconds for the oesophageal pressure transducer and 3 
milliseconds for the gastric pressure transducer, giving frequency responses of 92.5 




Figure 2-5: The response to a sudden decrease in pressure associated with 




2.2.2.7  Data acquisition and storage 
Amplified signals from the dual pressure catheter ie oesophageal and gastric 
pressures were recorded and displayed in real time on a desktop computer with 
Spectra® software version 3.0.0.9 (Grove Medical Ltd, U.K.) with 100 Hz 
analogue to digital sampling (PCI-MIO-16XE-50, National Instruments, Austin, 
USA ). Pressure signals were then transferred to laptop computer (Dell Optiplex 
170L) running Labchart software (v7.3.7 27, Powerlab 16SP, ADInstruments, 
Sydney, Australia) with analog to digital sampling at 100Hz (Powerlab 16SP, 
ADInstruments, Sydney, Australia). The data stored in the desktop computer was 
encrypted and transferred on to a secure laptop computer in the research office 
immediately after data acquisition which was secured by a laptop lock. Paper 
copies containing patient identifiable data were kept in a locked filing cabinet. 
2.2.2.8  Measurement of thoraco-abdominal asynchrony 
 
To provide data on thoracoabdominal synchrony, chest and abdominal wall motion 
was assessed using a non-invasive method of uncalibrated respiratory inductive 
plethysmography (RIP) (Respitrace Corporation, Ardsley NY, USA) in AC 
uncoupled mode. Inductance coils embedded in two elastic bandages were placed 
around the rib cage (RC) under the axillae and at the level of the umbilicus (AB). 
Output voltages from the RIP were proportional to the changes in band 
inductance which were in turn proportional to the changes in the underlying cross 
sectional area or excursions of the chest and abdomen. The voltages from both 




2.2.2.8.1 Analysis of TAA waveforms 
 
 
TAA was determined from ten artefact-free breaths during a five minute 
measurement period. For each breath, the rib cage (RC) and abdomen (ABD) 
movements were measured and a Lissajous figure plotted (Figure 2-6) with ABD 
movements on the x axis. Individual breaths were delineated by points of zero 
voltage (Figure 2-7).  Asynchrony between RC and ABD movements were 
quantified by determining the phase angle by comparing the difference between 
inspiratory and expiratory abdominal positions at mid-RC excursion (ABdiff) 
with the maximum abdominal excursion (ABmax). The phase angle φ was 
calculated as sin φ=ABdiff/ABmax.  When RC and ABD move in perfect 
synchrony, the phase angle is 0˚. As asynchrony appears the loop opens. 
Complete asynchrony (paradoxical movements) results in a phase angle of 










Figure 2-6: A trace demonstrating an asynchronous motion of the rib cage (RC) 
and the abdomen (AB) wherein the RC and AB motion are out of phase by 45 
degrees. ‘m’ is the width of the figure at mid RC excursion, and ‘s’ is the width 




















Figure 2-7: Lissajous figures and their respective phase angles (θ) 
demonstrating various degrees of asynchronous motion of the rib cage and the 
abdomen.  
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2.2.2.9 Transdiaphragmatic pressure time product (PTPdi) 
 
 
The transdiaphragmatic pressure time product (PTPdi) was measured as an index of 
the WOB in the randomised, crossover study comparing CPAP and HHFNC in 
prematurely born infants with evolving BPD. PTPdi was calculated breath by breath 
by integrating the area subtended by the transdiaphragmatic pressure during 
inspiration. Measurement and acquisition of Pdi is described above. The phase 
transition of respiratory flow is generally used to determine the start and end of 
inspiration. Because of the use of HHFNC, it was not possible, to measure 
respiratory flow directly in the study. The beginning of inspiration was 
determined, therefore, by the rise in Pdi at the start of a breath and end of 
inspiration was determined from rib cage movement using RIP (Figure 2-8 and 2-





Figure 2-8: Trace obtained from an infant showing Pgas, Pes, chest and 
abdomen signals obtained when infant was measured on CPAP mode. The 
shaded area depicts calculation of PTPdi which was obtained from the area 
subtended by the Pdi trace during inspiration.  
 




2.2.3 Measurement of diaphragm electrical activity (Edi)  
NAVA uses the electrical activity of the diaphragm (Edi), captured by a specialised 
nasogastric tube with an array of eight bipolar electrodes (Edi catheter), to servo 
control the applied ventilator pressure. The Edi is used both to trigger each inflation 
and also to determine the level of support proportional to the infant’s neural drive to 
breathe throughout each inflation (Navalesi and Longhini, 2015).  Signals from each 
electrode pair are differentially amplified, digitised, and processed. The signal is 
filtered to remove electrical contamination from the heart, esophagus, and 
environment to give the highest possible signal-to-noise ratio (Sinderby et al., 2007). 
Before insertion, the Edi catheter (Figure 2-10) (Maquet Critical Care AB) was 
dipped in sterile water for a few seconds to both activate the coating which improves 
electrical conductivity and to aid insertion. Edi catheter size and insertion distance 
for each patient was determined by the patient weight in kilograms and length in cm. 
The Edi catheter was inserted either oro or nasogastrically by measuring the “NEX” 
distance (the distance from nose, ear, and xiphoid) for proper insertion depth. The 
Edi catheter was inserted and correct positioning confirmed as per manufacturer 
instructions using the Edi catheter positioning guide function on the ventilator 
(Magnet Servo-n User Manual Version 1.1). The guide function displayed the 
retrocardiac echocardiograph. Correct positioning was achieved when the P waves 
and QRS complexes were visible in the uppermost leads and then decreased in size 
until the P waves disappeared in the lowest lead. Coloured highlighting of the central 
two leads appeared once the catheter was in the correct place (Figure 2-11). Once 
correct positioning was confirmed, the catheter was securely attached to the infant’s 
face using an adhesive dressing.  Stein et al (Stein et al., 2013b) evaluated the 
success or failure (due to complications) of placing the Edi catheter in 17 premature, 
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non-ventilated infants (average birthweight 1220 g, range 628-2520 g). The Edi 
catheter was placed successfully and correctly in all subjects, as determined by a 
dedicated “catheter positioning” window on the ventilator and no adverse events 
were noted (i.e. no pharyngeal, esophageal, or gastric damage or trauma, no apnea or 
bradycardia, and tracheal placement).  There was no deterioration in the Edi signal 
with different positions, or with feeds. 
Before the infant was changed to NAVA mode, the NAVA level was adjusted so that 
the estimated pressure waveform on NAVA closely matched the actual pressure 
waveform on the baseline settings, aiming for the peak Edi to be between 5-15µV as 
per the recommendations of the manufacturer. The baseline ventilator settings were 
used to determine the back-up settings to be used on NAVA in the absence of an Edi 
signal. The backup setting was the pressure setting when baby was on the ACV, 
default Edi trigger was 0.5 mcV and apnoea time set was 2 seconds. The upper 
pressure limit was at least five cm H2O higher than the baseline settings, but did not 
exceed 30 cm H2O. 
The highest Edi value of the waveform (Edi peak) represented neural inspiratory 
effort, responsible for the size and duration of the breath. The lowest Edi (Edi min) 
represented spontaneous tonic activity of the diaphragm, which prevents de-
recruitment of alveoli during expiration. The Edi trigger (µV; the minimum increase 
in electrical activity from the previous trough) triggered the ventilator to recognise 
the increase in electrical activity, thereby resulting in initiation of a breath. 
The NAVA level (cmH2O/µV; a conversion factor) translated the Edi signal into 
proportional pressures. Edi multiplied by the NAVA level determined airway 
pressure delivered by the ventilator for each breath. The NAVA software 
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automatically calculates peak inspiratory pressure (PIP) every seventeen minutes 
demonstrated by the formula   
 
PIP = NAVA level × (Edi peak − Edi min) + PEEP. 
 
Figure 2-10: NAVA - Edi Catheter 
1- Connection to the module used for electrical activity of the diaphragm (EAdi) 










Figure 2-11: Edi catheter positioning screen. Correct placement of the 
nasogastric tube shows the retro cardiac electrocardiogram (ECG) signal 
progressing from large p and QRS complexes in the upper leads to small or 




2.3  Statistical analysis 
 
Data were analysed for normality using the Kolmogorov-Smirnov, Shapiro-Wilk 
tests. Student’s t-test was used to compare normally distributed groups.  Non-
parametric data were analysed using the Mann Whitney U test and Wilcoxon signed 
rank test for paired data. The Chi Squared and Fisher’s exact test were used where 
appropriate. Data were deemed significant if the p value was less than 0.05. SPSS for 




Randomisation was carried out by random number table generation and selection of 
a sequential sealed envelope after successful recruitment and meeting of pre-defined 
entry criteria based upon gestational age. There were no gestational age strata for 





















3.1  Introduction 
 
During PAV, the applied pressure is servo controlled, based on continuous input 
from the infant’s breathing throughout each spontaneous breath. In addition, the 
ventilator can provide inflation pressure in phase with the tidal volume change in 
order to reduce the compliance load (i.e. the load due to the stiffness of infant’s 
lungs) and in phase with the flow change to reduce the resistance load (i.e. the load 
due to airflow obstruction), termed elastic and resistive unloading, respectively 
(Schulze, 2002). Very prematurely born infants developing or with established BPD 
will have stiff lungs (that is non-compliant) despite a very compliant chest wall, so 
may be particularly likely to benefit from elastic unloading. PAV has only been 
assessed in neonates in a few studies. In a previous crossover study, infants with 
evolving or established BPD on PAV compared to ACV had better oxygenation 
indices, a lower WOB and better respiratory muscle strength. The infants, however, 
were only studied on each ventilator mode for one hour (Bhat et al., 2015). The 
longest infants have been studied on PAV was four hours (Schulze et al., 2007), but 
during that study, only changes in pulse oximetry results were assessed. During 
PAV, the applied pressure is servo controlled throughout each breath, whereas 
during ACV, only the initiation of inflation is synchronised to the start of inspiration; 
hence, it is likely that oxygenation would be superior on PAV compared to ACV 
(Bhat et al., 2015). During PAV, however, it has been previously demonstrated that 
there is a trigger delay of 60 millisecond in an in vitro model (Patel et al., 2010a); 
hence, it was important to assess blood gases over a longer period than studied 
previously (Bhat et al., 2015). Hence, in this study the hypothesis that infants with 
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evolving or established BPD would have superior OI results after four hours on PAV 




A randomised, crossover study was undertaken. Infants were entered into the study if 
their parents gave informed written consent. The study was approved by the South 




Iinfants who were born prematurely (less than 32 weeks gestation) and who 
remained ventilated after the first week after birth were eligible for entry into the 
study if they were being supported by ACV. Evolving BPD was defined as ventilator 
dependence beyond seven days and established BPD as ventilator dependence 
beyond twenty-eight days. Infants were ineligible for inclusion in the study if they 





During the eight hour study period, no other changes were made to the infant care 
than the changes in ventilator mode. Infants at King’s College Hospital NHS 
Foundation Trust are routinely supported by the SLE 5000. The infants were 
transferred from the SLE 5000 ventilator to ACV on the Stephanie ventilator using 
the same ventilator settings (baseline). All infants as per the unit’s routine policy 
were ventilated via shouldered endotracheal tubes which have been shown to have 
minimal or no leaks (Hird et al., 1990).  
One hour was allowed for stabilisation of the infant on the Stephanie ventilator. A 
blood gas analysis was then performed and the baseline ventilator settings were 
noted. During the stabilisation period, the ventilator displayed compliance and 
resistance settings were noted every ten minutes and the six results meaned. The 
ventilator calculated the compliance from the inflation pressure (PIP - PEEP) and the 
resultant tidal volume. The value of the reciprocal of the compliance, elastance, was 
used to set the level of the elastic unloading. Each infant was then randomised to 
receive first either PAV or ACV mode for four hours and for the second four hours 
received the alternative mode.  
During ACV, the peak inspiratory pressure (PIP), PEEP and the inflation time were 
kept the same as at baseline. During PAV, the maximum PIP was set at 5 cm H2O 
above the PIP on ACV to prevent higher airway pressures. The PEEP level during 
PAV was the same as at baseline, and the PEEP and the inflation time during back 
up ventilation were the same as at baseline. Whenever cessation of spontaneous 
breathing occurred for more than five seconds during PAV, mandatory backup 
inflations were automatically delivered by the ventilator. The backup rate set at 40 
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breaths per minute was delivered to the infant for ten seconds with a backup inflation 
peak pressure of 5 cm H2O above the PIP used during ACV. Elastic unloading, 
which was used only during inspiration, was initially set at 75 % of full unloading. If 
after ten minutes the infant remained stable and no airway pressure waveform 
abnormalities were observed (Patel et al., 2010a), the unloading was increased to 100 
%. Full unloading was the level of unloading which increased the infant’s 
compliance to the expected ‘normal’, that is, 2.0 mL/cm H2O/kg. If airway pressure 
waveform abnormalities were then noted by looking at the pressure display, the 
unloading was to be reduced back to 75 %. Resistive unloading was not used as, an 
in vitro model, oscillations in the airway pressure waveforms appeared when the 
resistive unloading was greater than 100 cm H2O/L/s (Patel et al., 2010a). The 
number of desaturations oxygen saturation less than 88 %) on each mode was noted. 
An arterial blood sample was obtained at the end of each 4 hour period, the ventilator 
settings were noted and the OI was calculated. RR, Vt and MAP were obtained from 
the ventilator. The results from the last five minutes of the four hour study period 
were averaged. All the infants had continuous oxygen saturation monitoring. During 
the study, the inspired oxygen concentration was adjusted as necessary to maintain 





3.2.2 Sample size 
 
In a previous study, the mean OI in the PAV group was 6.0 (SD±2.4) and in the 
ACV group was 9.8 (SD±3.7) (Bhat et al., 2015). The planned sample size was 
eighteen infants to allow detection between the two ventilator modes of a within 
patient difference of 0.7 SD in the oxygenation index results with 80 % power and a 
two-sided significance of 5 %. 
 
3.2.3 Statistical analysis 
 
Differences were assessed for statistical significance using the paired Wilcoxon 






Recruitment to the trial was stopped at eight infants as all the OI results were in 
favour of PAV (Table 3.1). The decision was taken by the clinical team and the 
study statistician in the knowledge that the probability of all 8/8 results being in the 
same direction if both modes were in fact equally effective was extremely small 
(p=0.0039). 
The median BW of the eight infants was 767 (range 650 –1926) g, GA 25.7 (range 
24.4 – 33.5) weeks and postnatal age at measurement 19 (range 10 –105) days; seven 
of the eight infants were male. All the infants had been exposed to antenatal steroids 
and received postnatal surfactant and were receiving caffeine at the time of study. 
None were receiving sedation at the time of study or had received postnatal steroids. 
Their median baseline compliance was 0.4 (range 0.3–1.1) mL/cm H2O and 
resistance was 155 (range 66–252) cmH2O/L/s. All infants tolerated 100 % elastic 
unloading the study. The median FiO2 (p= 0.049), the median mean MAP (p=0.012) 
and the median OI (p=0.012) were all lower on PAV compared to ACV (Table 3-1). 
There was no significant difference in the median number of desaturation episodes 








PAV ACV Mode used first    
1  8.1  15.2 PAV   
2 7.0  8.3 PAV   
3 17.4  21.6 ACV   
4 12.6  20.3 PAV   
5 5.2  8.4 ACV   
6 10.0 14.1 PAV   








ACV   






















Table 3-2: Comparison by ventilator mode (n=8) 
The results are expressed as the median (range) 
 
 PAV  ACV  P value  
FiO 2 0.48 (0.31-0.65) 0.57 (0.40-0.72) 0.049 
PCO2 (kpa) 8.0 (5.5-9.4) 7.2 (5.5-11) 0.889 
OI 9.0 (5.2-17.4) 12.9 (8.3-21.6) 0.012 
MAP (cm H2O) 8.5 (6.7 -10.0) 9.5 (8.1 -13) 0.012 
Respiratory rate  56 (47-76) 57 (49-66) 0.401 
Tidal Volume (ml/kg) 7.5 (3.70-10.0) 5.8 (3.5-10.3) 0.093 
Saturations (Sao2) (%) 95 (92-97) 95(93-98) 0.571 
Desaturation episodes (n) 1 (0-2) 0 (0-2) 0.429 
117 
 
Table 3-3: Comparison by PAV ventilator mode used first (n=5) 
The results are expressed as the median (range) 
 
 PAV  ACV  p value  
FiO 2 0.52 (0.4-0.6) 0.55 (0.46-0.64) 0.343 
PCO2 (kpa) 8.1 (5.5-8.9) 6.9 (5.5-9.3) 0.686 
OI 8.1 (5.9-12.7) 14.1 (8.3-20.3) 0.043 
MAP (cm H2O) 7.7 (6.7-10) 8.5 (8.1-12) 0.042 
Respiratory rate  55 (48-77) 53 (50-61) 0.225 
Tidal Volume (ml/kg) 8.6 (4.1-9.6) 5.5 (3.5-10.3) 0.138 
Saturations (Sao2) (%) 96 (93-97)  95 (94-99)  0.480 
Desaturation episodes (n) 1 (0-1) 0 (0-2) 0.480 
Table 3-4: Comparison by ACV ventilator mode used first (n=3) 
 The results are expressed as the median (range) 
 
 PAV  ACV  p value  
FiO2 0.45 (0.31-0.65) 0.6 (0.4-0.72) 0.109 
PCO2 (kpa) 7.2 (7.0-9.32) 7.5 (6.4-11) 0.593 
OI 9.9 (5.2-17.4) 11.7 (8.5-21.6) 0.109 
MAP 9.3 (7.1-10) 10 (9-13) 0.109 
Respiratory rate 58 (55-70) 61 (57- 66) 1.00 
Tidal Volume (ml/kg) 6.7 (3.7-7.9) 6.3 (3.8-7.5) 0.285 
Saturations (Sao2) (%) 94 (94-98)  96 (93-97)  1.00 






This study has demonstrated that PAV compared with ACV in prematurely born 
infants ventilated beyond the first week after birth resulted in a reduced WOB and a 
lower OI. The lower OI is in keeping with the findings of Schulze and colleagues 
(Schulze et al., 2007), pulse oximetry readings were not significantly different on the 
two modes in very prematurely born infants (mean GA 25.6 weeks) with evolving 
CLD. In addition, in prematurely born infants with acute respiratory distress (birth 
weights between 600 and 1200 g) on 45-minute epochs on PAV compared with 45-
minute epochs on ACV or intermittent mandatory ventilation, similar arterial 
oxygenation was maintained despite lower airway and transpulmonary pressures 
during PAV (Schulze et al., 1999). The lower mean airway pressure and lower OI 
that this study has demonstrated on PAV likely reflect that during PAV the applied 
pressure is servo controlled throughout each spontaneous breath, whereas during 
ACV, synchronisation of inflation is only at the beginning of inspiration. In addition, 
the lower OI might also reflect the reduced level of asynchrony during PAV, which 
was not statistically significant (p=0.05). High airway pressures and airway pressure 
oscillations have been demonstrated when excessive amounts of elastic and resistive 
unloading are used (Schulze et al., 1998). Previous study (Bhat et al., 2015) was 
terminated before the calculated sample size, as all twelve infants in the one hour 
crossover study had lower OI results on PAV compared to ACV (Bhat et al., 2015). 
The maximum duration PAV was previously trialled was four hours (Schulze et al., 
2007), twenty two infants had a median GA of 25.6 weeks and were studied at a 
mean PNA of 22.9 days. They found after a four hour period of PAV that despite a 
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lower MAP, the inspired oxygen concentration and pulse oximetry readings were not 
significantly different between the two groups. Hence, it was important that four 
hour duration was tested for oxygenation indices when on PAV and compared with 
ACV. This study has demonstrated that four hour on PAV compared with four hour 
on ACV resulted in a significant improvement in the OI.  
On subgroup analysis, the results remained the same when analysis was done 
separately depending upon the start mode of ventilation ie PAV first however not 
when ACV was used first. This indicates that there was no cross over effect of the 
baseline ventilator mode and that four hour study is adequate to reliably note the 
differences between the two modes.  
There are limitations to this study. The postnatal age of infants studied had a wide 
range, studying infants at different stages of evolving BPD. Further stratifying based 
on the postnatal and gestational age would have been ideal however difficult in view 
of the small sample size.  
In conclusion, this short-term cross- over study has demonstrated that PAV 
compared to ACV was associated with significant superior oxygenation, which 











4 Chapter 4: Neurally adjusted ventilatory assist (NAVA) in very 























Application of mechanical ventilation in spontaneously breathing children remains a 
challenge for several reasons: mainly, small tidal volumes and high respiratory rates, 
especially in the presence of leaks, interfere with patient-ventilator synchrony. Leaks 
also cause unreliable monitoring of respiratory drive and respiratory rate (Vignaux et 
al., 2013). Furthermore, ventilator adjustment must take into account that infants 
have strong vagal reflexes, demonstrate central apnea and periodic breathing, with a 
high variability in breathing pattern (Beck et al., 2016).  
NAVA is a mode of ventilation whereby the timing and amount of ventilatory assist 
is controlled by the patient's neural respiratory drive. Since NAVA uses the 
diaphragm electrical activity (Edi) as the controller signal, it is possible to deliver 
synchronized assist, to follow the variability in breathing pattern, and to monitor 
patient respiratory drive, independent of leaks (Navalesi and Longhini, 2015).  
Infants with evolving or established BPD have a high resistance which means flow 
triggering can be challenging.  In addition, the severity of their lung function 
abnormalities likely means that supporting each breath throughout the inspiratory 
cycle would be advantageous. Hence, this study aimed to test the hypothesis that 







A randomised, crossover study was undertaken. Infants were entered into the study if 
their parents gave informed written consent. The study was approved by the West 




Infants were eligible for this randomised, crossover study if they were born at less 
than 32 weeks of gestation and remained ventilated at one week of age on ACV. 
Those with major congenital abnormalities or receiving neuromuscular blockade 
were excluded.  Infants at King’s College Hospital NHS Foundation Trust are 
routinely supported by the SLE 5000 (software versions 4.3; SLE Ltd., South 
Croydon, UK). All infants were ventilated with Coles shouldered endotracheal tubes 
which have been shown to have minimal or no leaks  (Hird et al., 1990). Volume 
targeting was not used. On entry into the study, the infants were transferred from 
ACV on the SLE 5000 to ACV (named ‘Pressure Control’ on the Servo-n ventilator, 
Maquet Critical Care, Solna, Sweden). The same ventilator settings and backup rate 
were used. In particular, the PEEP was kept at 4–5 cmH2O as had been used prior to 
the study and the inflation time was set, as previously, at 0.36 to 0.4 seconds. The 
back-up setting was set with apnoea time of two seconds and the upper pressure limit 
at least five cm H2O higher than the baseline settings, but did not exceed 30 cm H2O. 
The default Edi trigger was set at 0.5 mcv. A six French Edi catheter was inserted 
and correct positioning was confirmed as per the instructions of the manufacturer 
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using the Edi catheter positioning guide function on the ventilator (Magnet Servo-n 
User Manual Version 1.1).  
After one hour of stabilisation on the Servo-n ventilator using the settings described 
above, blood gas analysis was performed. Infants were then randomised to receive 
either ACV or NAVA first for one hour and then to receive the alternative mode for 
a subsequent hour. The order in which the infants received the two modes was 
randomised between each baby using a sequential opaque sealed envelope system. 
Before the infant was changed to NAVA mode, the NAVA level was adjusted so that 
the displayed pressure waveform on NAVA closely matched the actual pressure 
waveform on the baseline settings, aiming for the peak Edi to be between 5 and 15 
μV as per the recommendations of the manufacturer. The baseline ventilator settings 
were used to determine the backup settings to be used on NAVA in the absence of an 
Edi signal. The initial ventilator settings were noted, and the number and duration of 
desaturations (defined as oxygen saturation less than 88%) were noted on each 
ventilator mode. The inspired oxygen concentration (FiO2) was adjusted to maintain 
oxygen saturations between 92 and 96%. At the end of each hour, capillary blood gas 
analysis was performed and the OI calculated as FiO2 x MAP × 100/pO2. The FiO2, 
the PIP, MAP, Vt and respiratory system compliance (calculated from the tidal 
volume divided by the PIP) were recorded from the ventilator displays and averaged 
from the last five minutes of each one hour period. The data were down-loaded into 




4.2.2 Sample size 
 
The planned sample size was eighteen infants, as this allowed detection of a 
difference in OI between the two modes of one standard deviation (1SD), with 80% 
power and 5% significance. An interim analysis was planned to take place half way 
through, i.e. after nine patients, as a previous study with PAV, a ventilation mode 
which also provides tailored support throughout the infant’s inspiratory cycle, 
demonstrated that the OI on PAV was better in all patients than on ACV (Bhat et al., 
2015). In order to preserve the type I error at 5%, the interim analysis was conducted 
at 0.01 with the final analysis conducted using 0.04. If the interim analysis showed p 
< 0.01, then the trial was to stop and the final analyses was conducted using the nine 
patients. 
 
4.2.3 Statistical analysis 
 
The results were positively skewed and, therefore, log transformed for analysis so 
that a paired t test could be used. Using that method, the results including the mean 
and confidence intervals were on the ratio scale. Results were back-transformed to 
give geometric means for each mode of ventilation. The ratio of geometric means 
and the corresponding 95% confidence intervals for the ratio are presented. The ratio 
of the geometric means was interpreted as the percentage difference between results 
on NAVA compared to on ACV. The desaturation data were discrete and analysed 





At the interim analysis, the comparison of the OI on NAVA versus ACV was 
statistically significant using the modified cut-off for significance described above. 
The OI was lower on NAVA for all infants (Table 4-1). Hence, the clinical and 
statistics team agreed that the trial was to be stopped and the data analysed. Nine 
infants had been assessed, seven males and two females. Their median GA was 25 
(range 22–27) weeks and median BW 750 (range 545–830) grams. The infants were 
studied at a median PNA of 20 (range 8–84) days. Three infants with the highest 
OI’s median GA was 25 (range 25-26) weeks, BW 760 (range 760-794) grams and 
PNA when infants were studied 64 (64-84) days. This when compared with the 
remaining infants of median GA 25 (range 24-28) weeks, 750 (range 600-830) grams 
and PNA of 10.5 (range 8-21) days was not statistically significant.  All had received 
at least one dose of antenatal steroids and postnatal surfactant and were on caffeine 
at the time of the study. Only one infant was receiving sedation and this was at the 
same dose throughout the study. Five of the infants were studied first on NAVA and 
four on NAVA then ACV. Neither was there any suggestion that the order (by 
chance) was related to the size of value, i.e. no suggestion that all those with a high 
starting OI received the modalities in the same order (p=0.66). The ratio of the 
geometric means for the OI, the primary outcome, was 0.72 (NAVA/ACV), showing 
that the mean OI was 28% lower on NAVA compared to ACV with corresponding 
95% CIs from 62 to 83% (Table 4-1). Infants who had the highest OI’s on ACV 
tended to have a larger reduction in OI when studied on NAVA (Table 4-1). The 
mean PIP (p=0.017) and mean MAP (p =0.004) were significantly lower on NAVA, 
as was the mean FiO2 (p = 0.007). The mean compliance (p=0.005) and oxygen 
saturation (p=0.016) were significantly higher on NAVA. The OI results remained 
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statistically significant even without including the infants with highest OI’s 
(p=0.003). The means for the Vt, RR and peak Edi and the number of desaturations 




Table 4-1: Results by ventilatory mode 
 
Individual baseline PIP and FiO2 at the start of the study and individual OI data at 
the end of each study mode is given below. The mode which was used first in each 
















27 1 30.3 17.4 ACV 36.3 84 
16 0.44 9.2 8 NAVA 26.1 9 
18 0.63 7.6 5.7 NAVA 26.6 9 
18 0.27 6.7 4.6 ACV 26.4 8 
24 0.87 26.8 16 ACV 29.6 30 
19 0.41 7.4 6.6 NAVA 29.6 12 
19 0.7 24.1 13.4 NAVA 32.6 64 
18 0.45 6.4 5.4 NAVA 27.9 21 










Figure 4-2 OI data when infants randomised to ACV mode first 
 
 




Table 4-2: Results by ventilatory mode 
 
The results are presented as the geometric mean (range) for each mode, the ratio of 
geometric means between the two modes and the corresponding 95% CI 












































0.81  0.71 – 0.93 0.007 






































1.03 1.01 – 1.05 0.016 






This pilot study demonstrated that in infants born very prematurely and with 
evolving or established BPD, NAVA compared to ACV resulted in a significantly 
lower OI. This was associated with significantly lower PIPs and MAPs, likely 
reflecting that during NAVA the applied pressure is servo controlled throughout 
each inflation. On ACV, although inflation is triggered by the beginning of the 
infant’s inspiratory effort, the start of inflation may have been delayed as a flow 
trigger was used. Furthermore, after the inflation is triggered during ACV, neither 
the inflation pressure nor time is tailored to the infant’s inspiratory efforts. The 
higher compliance on NAVA compared to ACV reflects the lower PIPs with similar 
tidal volumes. A higher compliance on NAVA has been previously reported in 
neonatal and paediatric patients (Beck et al., 2009, Breatnach et al., 2010, de la Oliva 
et al., 2012). The study results suggest that infants with the highest OIs, i.e. the most 
severe lung disease, had the greatest reduction in OI during NAVA. This may reflect, 
as above, the shorter trigger delay on NAVA which means more of the infant’s 
breath is pressure supported. 
There are strengths and some limitations to this study. As the same ventilator was 
used for each mode, the significant differences demonstrated are due to the 
differences in the modes, rather than differences in the ventilator performance. 
Although infants were only studied for an hour on each mode, this study has 
demonstrated significant differences between the two modes. The infants included 
had a wide range of severity of respiratory disease as suggested by their PIP and 
FiO2, yet a positive effect of NAVA in all infants was noted. The infants had also 
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had a wide range of postnatal ages, but previous audits of 100 consecutive 
prematurely born infants demonstrated, 95% of those who remained ventilator 
dependent at one week developed BPD. Thus results demonstrate that compared to 
ACV, NAVA use was associated with superior results in infants with evolving or 
established BPD. Capillary blood samples were used to calculate the OIs. This 
method was used at the end of each of the two periods in all infants, thus the use of 
capillary blood sampling would not bias the results. The infants were all clinically 
stable when assessed and none were seriously ill, had shock, hypotension or 
peripheral vasoconstriction at the time of assessment (McLain et al., 1988). Thus, it 
was appropriate to calculate the OIs from the capillary blood samples. Only one 
infant was receiving sedation and this was at the same dose throughout the study, so 
this did not influence the results. A crossover study design was used as this removes 
the variability between patients by looking at effects within them. As no order effect 
was demonstrated, the design gives more precision. The trial was stopped at the 
planned interim analysis as in all infants the OI was lower on NAVA. There was no 
significant difference in the peak Edi between the two modes, although there was a 
trend for it to be lower on NAVA. This may have been due to insufficient 
redistribution of work from the patient to the ventilator, as the NAVA level was only 
adjusted so that the estimated pressure waveform closely matched the pressure 
waveform on the baseline settings. As yet, there are no randomised controlled trials 
with long-term outcomes assessing NAVA and therefore, any potential long term 




In conclusion, this study has demonstrated in a randomised crossover study that 
NAVA, compared to ACV, resulted in improved (lower) OI and this was associated 
with lower peak and mean airway pressures. There was no suggestion that the size of 
difference in OI was greater with order i.e. with either ACV then NAVA and 



















5 Chapter 5: Changes in use of heated humidified high flow nasal cannula 









5.1 Introduction  
 
HHFNC has gained popularity in many countries (Ojha et al., 2013, Hochwald O, 
2010, Hough et al., 2012, Manley et al., 2012, Roehr et al., 2007). Recent RCTs, 
however have not demonstrated any superiority of HHFNC (Collins et al., 2013a, 
Manley et al., 2013). Hence a survey was conducted with aim to determine whether 
use of HHFNC had changed since a previous survey in 2012 (Desai P et al, 2012).  
In addition, the survey aimed to also identify if and why practitioners preferred 
HHFNC or CPAP. 
 
5.2 Methods  
 
In 2015, lead clinicians of all 194 neonatal units in the UK were identified from the 
NNAP report, the BAPM directory and a departmental database from previous 
audits.  Clinicians were sent an email inviting them to complete an electronic web-
based survey using Survey Monkey (Appendix 1.3). Non-responders were sent email 
reminders and then contacted by telephone. In the 2012 survey, practitioners from 
the then 203 UK neonatal units had been contacted  (Desai P et al, 2012). Both 
surveys included questions on the level of neonatal care, the indications for use of 
HHFNC and the flow rates used. In addition, the 2015 survey also contained 
questions on nasal prong size, weaning policies and reasons for HHFNC or CPAP 




5.2.1 Statistical analysis 
 
Differences in the results of the two surveys were assessed for statistical significance 
using the chi-square test. IBM SPSS statistical software, V.22 (IBM Corporation, 
USA) was used.  
 
5.3 Results  
 
There was a 100% percent response rate to both surveys. Use of HHFNC had 
significantly increased in 2015 compared to 2012 (p<0.001) (Table 5.1). Almost all 
local neonatal and neonatal intensive care units were using HHFNC in 2015. 
Although fewer units were using HHFNC as an alternative to CPAP or weaning 
from CPAP (p=0.001), a greater proportion were using it as the primary support 
mode post extubation (p=0.001). The highest and lowest flow rates used varied in 
both surveys, but the magnitude of change of flow when weaning from HHFNC did 
not differ significantly in the two surveys. The flow rate tended to be weaned 24 
hourly. The 2015 survey highlighted that in 25% of units prong size was chosen to 
fit snugly and occlude the nostril and 36% of units had no HHFNC guideline. The 







Table 5-1: HHFNC practice in 2012 and 2015 
                 Data are displayed as the n (%) 
  2012 2015 P value 
HHFNC    
Total number of units  203 194  





Special Care Unit  12/53 (23%) 22/42 (52%) 0.003 
Local Neonatal Unit  60/92 (64%) 84/88 (95%) <0.001 




Data are subsequently displayed only for units using 
HHFNC 
 




Alternative to CPAP/ Weaning from CPAP 66 (58%) 65 (38%) 0.001 
Primary mode of respiratory support post extubation 47 (42%) 104 (62%) 0.001 
 
Highest Flow Rate 
  
 
8 36 (32%) 78 (46%) 0.011 
7 12 (11%) 6 (4%) 0.017 
6 38 (34%) 77 (46%) 0.030 
5 27 (23%) 8 (4%) <0.001 
 
Lowest Flow Rate 
  
 
4 11 (10%) 18 (11%) 0.485 
3 40 (35%) 40 (24%) 0.023 
2 45 (40%) 97 (57%) 0.003 
1 17 (15%) 14 (8%) 0.058 
 
Size of change in flow when weaning  
  
 
0.5 L/min 30 (27%) 51 (30%) 0.301 
1 L/min 38 (34%) 58 (35%) 0.504 
0.5 - 1 L/min 45 (40%) 60 (36%) 0.271 
 





79 (47%)  
24-48 hourly 
 
21 (12%)  
48 hourly  
 
17 (10%)  
Depends on the infant’s condition   52 (31%)  
 
Prong size    
 
Snug fit to occlude the nostril   42 (25%)  
Prong size selected to allow air leak   127 (75%)  
Guideline/Policy  





Table 5-2: Preference for CPAP or HHFNC 
 
Data are displayed as n (%)* 
 
 
 CPAP HHFNC P value   
 








Better access to the infant 1 (1%) 145 (86%) <0.001  
Easier to set up 13 (8%) 138 (82%) <0.001  
Better  access for  skin to skin 
care 
0 (0%) 162 (96%) <0.001  
Quicker to achieve full bottle 
feeding 
0 (0%) 166 (98%) <0.001  
Quicker to achieve full breast 
feeding 
0 (0%) 168 (99%) <0.001  
Less nasal trauma 0 (0%) 162 (96%) <0.001  
More comfortable for the 
infant 
1 (1%) 165 (98%) <0.001  
Parental preference 0 (0%) 162 (96%) <0.001  
 













5.4 Discussion  
 
Comparison of the results of surveys has demonstrated that there has been a 
significant increase in the use of HHFNC between 2012 and 2015. Units are now 
significantly more likely to use HHFNC rather than CPAP as the primary support 
mode post extubation. This is despite a lack of evidence that HHFNC provides more 
efficacious respiratory support (Shetty and Greenough, 2014). This change in 
practice then reflects practitioners’ views on other advantages to the infant that may 
occur during HHFNC support.    
The most commonly used devices were Vapotherm 2000i and the Optiflow TM 
(Fischer and Paykel). Similar observations were made in a survey in the United 
States (Hough et al., 2012). HHFNC was used as primary treatment post-extubation 
from MV in sixty-two percent of the neonatal units in Australia and New Zealand 
(Hough et al., 2012). Survey done by Ojha et al (Ojha et al., 2013) showed fifty-three 
percent of the neonatal units used HHFNC post-extubation . In a randomised trial of 
432 infants of 28–42 weeks of gestational age, no significant difference was seen in 
early extubation failure (less than 72 hours) between infants on HHFNC (10.8%) and 
nCPAP (8.2%) (Yoder et al., 2013). Collins et al. (Collins et al., 2013a), randomly 
assigned 132 infants less than 32 weeks of gestational age to receive either HHFNC 
or nCPAP post extubation. No significant differences were found in the primary 




During HHFNC, airway pressure increases with the nasal prong to nares ratio. As a 
consequence it has been recommended that the prong diameter should be about half 
that of the nostril (Hochwald O, 2010). Yet, 25% of units were using prongs of a size 
to occlude the nostril.  Weaning flow in increments of between 0.5 -1 L/min and 24 
hourly were most popular, but there was no consensus. This likely reflects that there 
is currently no evidence to determine the best weaning strategy from HHFNC. As a 
consequence, infants may stay on HHFNC longer than on CPAP (Gupta A, 2014).  
HHFNC was thought to be better than nCPAP by the majority (64%) of responders. 
Similarly a survey of nursing staff demonstrated 76.9 % of nurses preferred HHFNC 
over NCPAP in infants equal to or older than 28 weeks of gestational age (Roberts et 
al., 2014). Practitioners reported that the majority of parents favoured HHFNC over 
CPAP. A likely influence on parental preference is that almost all practitioners who 
responded to our survey thought that HHFNC facilitated easier access to skin to skin 
care, was more comfortable for the infant, caused less nasal trauma and facilitated 
earlier achievement of full enteral feeds. The evidence for those beliefs, however, is 
mixed. A randomised, crossover comparison of 24 hours of  nCPAP or HHFNC then 
24 hours of the alternative support  in infants with mild respiratory illness 
demonstrated that, although parents preferred HHFNC, there were no significant 
differences in the results of a patient comfort score (Klingenberg et al., 2014). Injury 
to the nasal mucosa or external nares has been frequently reported in prematurely 
born infants supported by nCPAP (Newnam et al., 2013, Fischer et al., 2010), and 
several studies have demonstrated a lower incidence of nasal trauma with HHFNC 
compared to HHFNC (Manley et al., 2013, Yoder et al., 2013, Kugelman et al., 
2015). Infants born extremely prematurely may remain on respiratory support for 
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many months, including the age when they should be able to take oral feeds, that is 
usually at 34 weeks PMA (Mizuno and Ueda, 2003, Gewolb et al., 2001, Lau et al., 
2000). The likelihood of a trial of breast or bottle feeding may be higher if the infant 
is supported by HHFNC rather than CPAP, but that evidence is only from a 
retrospective review (Yoon SH, 2011) .   
This study has a number of strengths and some limitations. Unlike previous surveys 
of HHFNC, this survey had a 100% response rate in 2015 as did the comparator 
survey in 2012. In addition, all levels of units completed the survey. As with all such 
surveys, the responses may reflect the views of the practitioner answering the survey 
rather than the unit’s policy. Sixty-four percent of units, however, did have an 
HHFNC policy/guideline so it does feel that our results are likely to reflect UK 
practice in 2015.   
In conclusion, use of HHFNC has significantly increased in UK neonatal units, in 
particular as the primary support mode post extubation.  Those data and the lack of 
consensus on weaning strategies highlights research is urgently needed to optimise 
















6 Chapter 6: Work of breathing during CPAP and heated humidified high 














6.1 Introduction:  
 
Non-invasive respiratory management of infants with evolving or established BPD is 
particularly challenging as such infants often tolerate CPAP poorly. Whether CPAP 
or HHFNC provides more effective respiratory support has not been assessed in such 
a population. Hence, the aim of this study was to determine in infants with evolving 
or established BPD whether CPAP compared to HHFNC reduced the WOB and 




A randomised, crossover study was undertaken. Infants whose parents gave informed 
written consent were entered into the study. The study was approved by the London 






Infants born at less than 32 weeks of gestation between April 2014 and February 
2015 at King’s College Hospital NHS Foundation Trust, London, UK and required 
CPAP and more than 40% of oxygen at or beyond two weeks of age were eligible for 
entry into this study.  Those infants with a postnatal age greater than 14 days but less 
than 28 days were diagnosed as having evolving BPD and those aged 28 days or 
older established BPD.  Infants whose parents gave informed written consent were 
entered into the study.   
Infants were studied on two days for two hours each on CPAP (SLE 2000 or 5000 
infant ventilator) and HHFNC (Fisher and Paykel using optiflow TM neonatal and 
infant nasal prongs). Infants were randomised on the first day to be supported on 
either CPAP or HHFNC for two hours and then by HHFNC or CPAP for two hours, 
on the second day the modes were delivered in the reverse order. The CPAP level 
was 6 cm H2O and during HHFNC a flow rate of 8 L/min was used for infants with a 
weight more than 1 kg and 6 L/min for infants with a weight less than 1kg. WOB, as 
the PTPdi was assessed and TAA determined. 
 
6.2.2 Sample size 
 
Recruitment of twenty infants allowed us to detect a difference of twenty-five 
percent in the WOB between the groups and differences in the results of the other 
physiological measurements equivalent to one standard deviation with 80 % power 




6.2.3 Statistical Analysis 
 
The data were tested for normality and found to have a normal distribution, hence a 
paired t-test was used to assess whether differences were statistically significant. 
There was no evidence for any effect of the order or of the day in the results, hence 
the results for each of the two respiratory support modes were averaged over the two 
days. Regression models were used to examine the effect of the order of modes of 
respiratory support (CPAP/HHFNC or HHFNC/CPAP). The residuals from the 
regression model were checked for their fit to a normal distribution. Because of the 
relatively small sample size and the difficulty in ensuring a normal distribution, the 
analysis examining mode was also run using a rank test (Wilcoxon matched pairs) 
which gave similar results. IBM SPPS statistical software, V.22 (IBM Corporation, 




Parents of thirty eligible infants were approached and twenty agreed to recruitment.  
The infants who were recruited compared to those who were not did not differ 
significantly with regard to their GA (27 (range 25–29) weeks versus 28 (range 25-
32) weeks) (p=0.47) or BW (median 834 (664–1020) grams versus 880 (range 512-
1500) grams) (p=0.94). When studied the infants required a median FiO2 of 0.42 
(range 0.4-0.58) (Table 6-1). There were no significant differences in the results of 




Table 6-1: Demographic data  
The data are presented as median (range) or n (%) 
Number of infants recruited (n) 20  
Gestational age (weeks)  28 (24-32) 
Gestational age ≥ 28 weeks  7 (35%) 
Birth weight (grams) 888 (512-1500) 
Antenatal steroids 18/20 (90%)  
Surfactant 20/20 (100%)  
Caffeine 20/20 (100%)  
Post conceptional age (weeks) at assessment 31 (28-39) 
Postnatal age (days)  23 (15-96) 
Male (%) 11/20 (55%) 
Ethnicity:  
    Caucasian 8 (40%) 
    Afro-Caribbean 5 (25%) 
    Asian 5 (25%) 
    Other 2 (10%) 
 
 
Table 6-2: Physiological assessment results by respiratory support mode  
The results are expressed as the median (range) 
 CPAP  HHFNC  P value  
PTP cmH20/s/min 244 (126-294) 220 (169.5-318) 0.852 
TAA (degrees) 12.6 (4.5-23.3) 13.1 (4.2 -23.8) 0.763 
HR (bpm) 153 (130-172) 152 (140-175) 0.93 
RR (bpm) 55 (35-79) 55  (38-74) 0.78 
Oxygenation 
Saturation (%) 







This study has demonstrated that in prematurely born infants with evolving or 
established BPD, there were no significant differences in the WOB, TAA or SaO2 
when the infants were supported by CPAP or HHFNC. Infants with evolving or 
established BPD were studied exclusively, unlike in previous studies (Lavizzari et 
al., 2014, Saslow et al., 2006, de Jongh et al., 2014). Interestingly, in the one study 
which did include infants with BPD, but also other pathologies, no significant 
difference was found in the WOB between CPAP and HHFNC (Saslow et al., 2006).  
This study has a number of strengths and some limitations. A dual pressure tip 
transducer was used to assess the WOB as assessed by measurement of the 
transdiaphragmatic pressure time product. Changes in oesophageal pressure may not 
accurately reflect change in pleural pressures when chest wall distortion results in an 
uneven distribution of pleural pressure changes. In this study, there were no 
differences in the TAA between the two respiratory support modes; hence the 
comparison of the WOB results is valid. A crossover design was used, hence we 
cannot comment on long term outcomes.  Previous studies investigating the WOB 
were also of a crossover design (Saslow et al., 2006, Lavizzari et al., 2014, de Jongh 
et al., 2014), but were of single crossover design and did not analyse the effect of the 
order in which the infants were studied on a particular respiratory mode. This study 
examined infants on two successive days with the order of respiratory support mode 
being reversed on the subsequent day and then the results of two days were meaned. 
It is possible had the infants been exposed to longer periods of HHFNC and CPAP 
different results may have been obtained. Assessment of ten very low birth weight 
infants in a crossover design study of two hours on HHFNC (mean flow rate of 4.8 
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or 5.4 l/min) or CPAP (5 cm H2O) demonstrated greater diaphragmatic activity on 
HHFNC suggesting that nCPAP was providing more effective respiratory support. 
Of note, however, there was no significant difference in the oxygen saturation levels 
between the two modes (Nasef et al., 2015).   
In conclusion, this study has demonstrated that CPAP did not provide superior 
respiratory support as determined by physiological assessments compared to 
























7 Chapter 7: Discussion  
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7.1  Summary and current literature  
 
7.1.1 Invasive ventilation studies (PAV and NAVA)  
 
In Chapter 3, the randomised crossover study of PAV versus ACV demonstrated that 
PAV compared to ACV in prematurely born infants with evolving or established 
BPD, was associated with significant superior oxygenation which likely reflects the 
better synchronisation of the inflation pressure and tidal volume throughout 
inspiration.  There have been no recent studies examining PAV in premature infants 
that have been published. The findings from the studies undertaken by our research 
group (Bhat et al., 2015, Shetty et al., 2016) and by Schulze et.al.(Schulze et al., 
2007) in premature infants have shown promising results but a randomised 
controlled trial with infants on PAV for a duration longer than four hours with long-
term outcomes is needed to evaluate if any benefit is appreciable in the long term 
before routine clinical use. Ventilation strategies designed to improve patient-
ventilator ‘interaction’ have continued to evolve, of which NAVA is an example. 
Some authors believe that NAVA is more suitable for a wider range of infants than 
PAV including the most premature infants, due to more accurate triggering and 
delivery of ventilator support regardless of leak around the endotracheal tube 
(Kacmarek, 2011).  
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In Chapter 4, a randomised crossover study demonstrated that NAVA compared to 
ACV, resulted in improved (lower) OI and reduced peak and mean airway pressures. 
In the neonatal population NAVA has been compared in a number of crossover trials 
to date to modes such as PSV and ACV (Lee et al., 2012, Stein et al., 2013a, 
Longhini et al., 2015). Data from these studies suggest an improved patient 
ventilator synchrony, lower peak pressures with a lower work of breathing. In a 
retrospective single centre study (Jung et al., 2016), where twenty-nine preterm 
infants with a median gestational age of 25.4 weeks (range, 23.4-30.3 wk) and a 
median birth weight of 680 grams (range, 370 - 1,230 grams) and who were 
supported with a mechanical ventilator for more than four weeks were converted to 
NAVA. During NAVA, the peak inspiratory pressure (20.12 ± 2.93 vs 
14.15 ± 3.55 cm H2O; p < 0.05), mean airway pressure (11.15 ± 1.29 vs 
9.57 ± 1.27 cm H2O; p < 0.05), and work of breathing (0.86 ± 0.22 vs 0.46 ± 0.12 J/L; 
p < 0.05) were significantly decreased, and the blood gas values were significantly 
improved. In an another study (Lee et al., 2017) of fourteen  prematurely born 
patients who received prolonged ventilation, NAVA reduced cyanotic episodes and 
the need for sedatives and dexamethasone. NAVA has also been used in improving 
patient-ventilator synchrony, reducing endotracheal secretion and gastric over 
distention in a rare skeletal dysplasia (Jeune syndrome -asphyxiating thoracic 
dystrophy) (Cosi et al., 2016) and also there are case reports of use in unilateral 
diaphragmatic paralysis (Roosens et al., 2016). However, larger RCTs are needed to 




7.1.2   Non-invasive ventilation studies  
 
In chapter 5, I have shown that use of HHFNC has significantly increased in UK 
neonatal units, in particular as the primary support mode post extubation but 
concluded that the lack of consensus on weaning strategies highlighted that research 
is urgently needed. The recent Cochrane review (Farley et al., 2015) also concluded 
that there is currently no evidence available to suggest the best strategy for weaning 
and withdrawing HHFNC as a respiratory support in preterm infants.  
In Chapter 6, I have demonstrated that CPAP did not provide superior respiratory 
support compared to HHFNC in infants with evolving or established BPD.  HHFNC 
was not significantly different in efficacy from nCPAP or NIPPV in respiratory 
support after extubation in a Cochrane meta-analysis (Wilkinson et al., 2016). In 
another systematic review (Fleeman et al., 2016) concluded that there was lack of 
convincing evidence suggesting that HHFNC is superior or non-inferior to usual 
care, in particular NCPAP. Both of these studies, however, looked at non-invasive 
forms of respiratory support in preterm infants immediately after birth or following 
extubation. There have been no further studies examining WOB in BPD and hence a 
larger randomised study would be beneficial in the future.   
A pilot study to determine the feasibility of using HHFNC in stabilisation of babies 
born less than 30 weeks gestation in delivery suite in a single-centre (Reynolds et al., 
2016), concluded HHFNC for stabilisation of premature infants in the delivery room  
and subsequent transfer to NICU is feasible. Whether this would prevent the number 
of BPD infants is yet to be determined.   
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Non-invasive Neurally Adjusted Ventilator Assist (NIV-NAVA) has been 
introduced via a pilot and a randomised observational study to assess its safety, 
feasibility, and short term physiological effects (Gibu et al., 2017). The pilot protocol 
applied NIV-NAVA to eleven infants on nasal CPAP, HHFNC, or nasal IMV 
(NIMV), in multiple two to four hour periods of NIV-NAVA for comparison. The 
NAVA catheter was used for eighty one patient day’s without complications. NIV-
NAVA produced significant reductions (as a percentage of measurements on NIMV) 
in: PIP, 13%, FiO2, 13%, frequency of desaturations, 42%, length of desaturations, 
32%, and phasic Edi, 19%. NIV-NAVA is projected as a safe, alternative mode of 
non-support that produced beneficial short-term physiological effects, especially 
compared to NIMV. If NIV-NAVA was the future of NIV is yet to be determined.  
In a retrospective analysis (Colaizy et al., 2016) of a cohort of twenty-four VLBW 
(<1.5 kg) ventilation improved after an increase in NIV NAVA level in 83% of the 
premature infants studied (20/24) with a decrease in median pCO2 by 5 mm Hg 
(p = 0.0001). They concluded that NIV NAVA can provide synchronised post-
extubation ventilatory support as measured by decreased pCO2 in premature infants. 
Our patient group have been infants with evolving or established BPD and to 




7.2 Strengths and weaknesses of the studies 
 
7.2.1 Invasive ventilation studies (PAV and NAVA)  
 
We stopped the trial at the planned interim analysis in both the studies in Chapter 3 
and 4, as all infants in both these studies had OI’s that were lower on NAVA and 
PAV compared to ACV. Hence our sample size is comparatively low.   In the NAVA 
study, we used capillary blood samples to calculate the OIs. We used this method at 
the end of each of the two periods in all infants.  The infants were all clinically stable 
when assessed and none were seriously ill, had shock, hypotension or peripheral 
vasoconstriction at the time of assessment (McLain et al., 1988). Thus, it was 
appropriate to calculate the OIs from the capillary blood samples, however arterial 
blood gas analysis would have been ideal.  
Ages of infants studied in above studies were wide ranged ie 10 -105 days in Chapter 
3 study and 8-84 days in Chapter 4. As per inclusion criteria we have included all 
infants who required ventilation beyond first week of life. However, in view of the 
small sample size it would be would be difficult to tease out evolving and 




7.2.2 Non-invasive ventilation studies 
 
One of the main strengths of our study in Chapter 6, comparing WOB between 
CPAP and HHFNC in evolving and established BPD is that  infants were studied on 
two successive days with the order of respiratory support studied being reversed on 
the subsequent day and the results were then meaned, hence the results are robust. 
The measure of WOB, PTPdi was calculated by breath by breath integration of the 
area subtended by the transdiaphragmatic pressure during inspiration. The phase 
transition of respiratory flow is generally used to determine the start and end of 
inspiration. Because of the use of HHFNC, it was not possible, to measure 
respiratory flow directly in the study. The beginning of inspiration was determined, 
therefore, by the rise in Pdi at the start of a breath and end of inspiration was 
determined from rib cage movement using RIP. The same method was used for both 




7.3 Future work  
 
Both PAV and NAVA, respiratory support is servo-controlled based on continuous 
input from the infant’s respiratory effort. Both aim to improve synchronisation of the 
timing of the respiratory cycle and also to vary the level of support offered breath-to-
breath in proportion to the respiratory effort of the patient.  In this thesis, both PAV 
and NAVA have been shown to have advantageous in neonates, but they have not 
been compared to each other and should be. Studies evaluating NAVA with other 
modes of ventilation have been small. Since VTV has been shown to improve both 
short term and long term outcomes in prematurely born infants, randomised trials 
comparing NAVA with VTV in newborns to see if NAVA is superior to VTV would 
be useful. As most previous studies and trials were small and did not include long-
term patient oriented outcomes, randomised controlled trials are needed to determine 
whether NAVA is effective in decreasing the duration of ventilation, reducing the 
incidence of BPD and decreasing LOS, rate of pneumothorax and IVH. 
Non-invasive Neurally Adjusted Ventilator Assist (NIV-NAVA) has been 
introduced into clinical practice via a pilot and a randomised observational study to 
assess its safety, feasibility, and short term physiological effects (Gibu et al., 2017). 
The improvements in oxygenation and the reduction in the frequency and severity of 
episodes of desaturation, if sustained on NIV-NAVA, could make a difference in the 
long-term outcomes of BPD or retinopathy of prematurity. Well-designed feasibility 
studies are needed to assess the safety of NIV-NAVA and its possible longer term 
physiological benefits, which make it a feasible alternate therapy to all current 
modalities of non-invasive ventilation.  
157 
 
A pilot study to determine the feasibility of using HHFNC in stabilisation of babies 
born less than 30 weeks gestation in delivery suite in a single-centre (Reynolds et al., 
2016), concluded HHFNC for stabilisation of premature infants in the delivery room  
and subsequent transfer to NICU is feasible. If these finding are generalisable is yet 




PAV and NAVA may be beneficial in infants with evolving or established BPD. Use 
of HHFNC has significantly increased in UK neonatal units. In infants with evolving 
or established BPD, CPAP compared to HHFNC offered no significant advantage 
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INFORMATION SHEET         
(19/10/2013, Version 6) 
 
  
Optimisation of neonatal ventilation – proportional assist ventilation (PAV) 
 
We are inviting you to consider allowing your baby to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you wish. Take time to 
decide whether or not you wish your baby to take part. 
 
Why are we doing it? 
A significant proportion of babies admitted to the neonatal unit require help via a machine (ventilator) for their 
breathing. The survival of such babies has improved dramatically over the years, but complications such as 
chronic oxygen dependency and other breathing problems at follow-up remain unchanged. New types of 
ventilation have been developed in the hope their use may reduce the breathing problems. It is important these 
new types of ventilation are used in the best possible way. One is called proportional assist ventilation (PAV), 
which delivers support in proportion to the infant’s breathing efforts.  Our aim is to determine whether PAV offers 
any advantages for the baby over assist controlled ventilation (patient triggered ventilation), a form of pressure-
limited ventilation, during which ventilator breaths are delivered at a pre-set pressure.   
 
How will we do it? 
We will assess babies that are still requiring support from the breathing machine at over a week of age who are 
receiving assist controlled ventilation. Babies will be randomly assigned to either assist controlled ventilation or 
PAV and they will spend four hours each on PAV and assist controlled ventilation. At the end of each four hour 
period we will measure your baby’s muscle strength and the work associated with breathing (work of breathing). 
To measure the work of breathing we will use a tube similar to your baby’s nasogastric (feeding) tube. Once the 
measurements are made on both the ventilator modes, your baby will go back to the same mode he/she was on 
before the study. 
 
Are there any disadvantages of taking part in the study? 
There are no known risks to your baby from taking part in this study. 
 
How will the information be shared? 
All information that is collected will be kept strictly confidential. We will, with your consent, inform your GP of your 
child’s involvement in this study.   
 
Giving Consent 
It is important you understand that this study is voluntary and for research purposes.  You may choose not to 
allow your child to participate in this study and you may withdraw your child at any time without their medical care 
or legal rights being affected.  If you require any further information please ask. There are no harmful side effects 
associated with this study.  No indemnity is available, although, normal NHS procedures apply in the unlikely 
event of any adverse outcome of the study.   
   
If you decide to allow your child to take part in the study, you will be given a copy of the information sheet and 
consent form to keep.  All information that is collected during the course of the research will be kept strictly 
confidential and if the results are published then anonymity will be maintained. This study was reviewed and 
approved by the Research Ethics Committee of King's College Hospital NHS Trust. 
 
Thank you very much for considering your child for enrolment into this project. If you are happy to participate 
please sign below. If you have any further questions or would like to meet with a member of the research team to 









(19/10/2013, Version 6) 
 
 
Patient Identifier number    NB Three copies should be made, for 
for this trial:   ………………… (1) patient, (2) researcher, (3) hospital notes 
 
Title of Project: Optimisation of neonatal ventilation 
 
                Please initial 
box 
1. I confirm that I have read and understand the information 
sheet dated 19/10/2013 for the above study and have 
had the opportunity to ask questions.  
 
2. I understand that my child’s participation is voluntary and that I  
am free to withdraw at my child at any time, without giving any  
reason, without my child’s medical care or legal rights being affected. 
 
3. I understand that sections of any of my child’s medical notes may  
be looked at by responsible individuals or from regulatory 
authorities where it is relevant to my taking part in research. 
I give permission for these individuals to have access to my child’s 
records. 
 






















A 1.2 Patient information sheet and Consent form for Chapter 4 
 
         




(01/10/2015, Version 3) 
 
Neurally Adjusted Ventilator Assist (NAVA) versus Assist control ventilation  
 
We are inviting you to consider allowing your baby to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you wish. Take time to 
decide whether or not you wish your baby to take part. 
 
Why are we doing it? 
Many babies admitted to the neonatal unit require help via a breathing machine (ventilator). The survival of such 
babies has improved over the last twenty years, but long-term complications such as chronic oxygen 
dependency and chronic breathing problems remain unchanged.  
 
Modern ventilators attempt to match the patient’s needs as much as possible but are not capable of knowing 
exactly when a patient wants a breath. The ventilator may give breaths even when the patient is not ready and 
this may cause some discomfort. 
 
A new monitoring tool called NAVA is now available that measures exactly how much “breath” a baby needs to 
be comfortable. This is a special computerised module that attaches to the ventilator  that can work out exactly 
how much power the diaphragm is generating or needs (the diaphragm is the main respiratory muscle that does 
all the breathing). The tool is very simple in that it is a special nasogastric tube (one that we ordinarily use to feed 
babies) that has electrodes in it that measure the power of the diaphragm. It is very much like an ECG for the 
heart, but only for the breathing muscles. This special nasogastric tube provides an instant feedback to the 
ventilator of how much breath is required and the ventilator then delivers every breath as demanded by the 
patient every second. NAVA has been used in adults and children including premature babies and has proven 
very useful in optimising patient comfort on ventilators.  
 
Our aim is to determine whether NAVA offers any advantages over standard pressure limited ventilation. 
 
How will we do it?  
We wish to assess babies who are born prematurely and remain supported by a breathing machine one week after 
birth because of their breathing problems. Babies will be randomly assigned to either assist controlled ventilation or 
NAVA and they will spend one hour each on NAVA and assist controlled ventilation.  At the end of each one hour 
period we will measure the baby’s muscle strength and the work associated with breathing (work of breathing). To 
measure the work of breathing we will use an additional tube similar to the baby’s nasogastric (feeding) tube. A 
small blood sample will be taken at the end of each hour from the baby’s indwelling catheter, that is there are no 
extra pricks, to assess the levels of oxygen and carbon dioxide (the waste gas). Once the measurements are 
made on both the ventilator modes, your baby will go back to the same mode he/she was on before the study. 
 
Are there any disadvantages of taking part in the study? 
There are no known risks to your baby taking part in this study. The procedure may cause some disturbance 
when changing the breathing apparatus, but every effort will be taken to minimise this. If at any point during the 
study, researcher feels that your child is not ready for the study, and then your child will be put back onto the 











What happens if something goes wrong? 
Your baby will be closely monitored throughout the study in case any issues do arise. If you do have any 
concerns about any aspect of this study, you should speak to the researchers, using the contact details below, 
who will do their best to answer your questions. If you remain unhappy and wish to complain formally, you can do 
this by contacting the Patient Advice and Liaison Service (PALS) via phone (0203 299 3601) or email (kch-
tr.PALS@nhs.net). 
 
How will the information be shared? 
All information that is collected will be kept strictly confidential. We will, with your consent, inform your GP of your 
child’s involvement in this study, by stating it in your baby’s discharge summary. 
 
Who has reviewed the study? 
 




It is important you understand that this study is voluntary and for research purposes.  You may choose not to 
allow your child to participate in this study and you may withdraw your child at any time without their medical care 
or legal rights being affected.  If you require any further information please ask. There are no harmful side effects 
associated with this study.  In the event that something does go wrong and your baby is harmed during the 
research and this is due to someone's negligence then you may have grounds for a legal action for 
compensation against King's College London or King's College Hospital NHS Trust, but you may have to pay 
your legal costs.  
 
If you decide to allow your child to take part in the study you will be given a copy of the information sheet and 
consent form to keep.  All information that is collected during the course of the research will be kept strictly 
confidential and if the results are published then anonymity will be maintained. This study was reviewed and 
approved by the West Midlands – Solihull Research Ethics Committee.  
 
Thank you very much for considering your child for enrolment into this project. If you are happy to participate 
please sign below. If you have any further questions, or would like to meet with a member of the research team 



















(01/10/2015, Version 3) 
 
 
Patient Identifier number    NB Three copies should be made, for 
for this trial:   ………………… (1) patient, (2) researcher, (3) hospital notes 
 
 




                Please initial 
box 
2. I confirm that I have read and understand the information 
sheet dated 01/10/2015  for the above study and have 
had the opportunity to ask questions.  
 
3. I understand that my baby’s participation is voluntary and that I  
am free to withdraw at my baby at any time, without giving any  
reason, without my baby’s medical care or legal rights being affected. 
 
4. I understand that sections of any of my baby’s medical notes may  
be looked at by responsible individuals or from regulatory 
authorities where it is relevant to my taking part in research. 
I give permission for these individuals to have access to my baby’s 
records. 
 
5. I consent for my GP to be informed of my baby’s inclusion into the study 
 
 
































































A 1.4 Patient information sheet and Consent form for Chapter 6 
INFORMATION SHEET 
(11/03/2014, Version 2) 
  
        
           
            
Comparison of the work of breathing during humidified high flow nasal cannula oxygen (HHFNC) and 
continuous positive airways pressure (CPAP). 
 
We are inviting you to consider allowing your baby to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends, relatives and your GP if you wish. Take time to 
decide whether or not you wish your baby to take part. 
 
Why are we doing it? 
 
This study is being carried out to determine whether babies have to work less hard to breathe (work of breathing) 
on HHFNC or CPAP. Both forms of breathing support are used as a step down when babies no longer need help 
from the breathing machine (extubated), but still need some support for their breathing. During HHFNC, the 
breathing gas is delivered at high flows, during CPAP lower flows are used and higher pressures can be given. 
Both techniques are delivered via nasal cannulae, that is small tubes inserted just inside the nostrils. When 
babies are taken off the ventilator they have to work harder to breathe and it is not clear whether HHFNC or 
CPAP better supports babies, that is they have a lower work of breathing. The work of breathing is particularly 
important in babies who are chronically dependent on breathing support, that is they require breathing support 
beyond two weeks after birth, if the baby is working hard to breathe this can slow down their weight gain. We, 
therefore wish to determine whether HHFNC or CPAP better supports in babies who are chronically dependent 
on respiratory support and which is associated with the lower work of breathing. 
 
How will we do it? 
 
Much of the information we need for this study can be obtained from the medical and nursing teams caring for 
your baby, but we do need to make some additional measurements. On two successive days, babies will be 
studied for two hour periods on the two types of breathing support, CPAP and HHFNC.  The order in which they 
will be studied will be chosen by random, that is as tossing a coin.  The order in which the breathing support 
modes will be studied will be reversed on the next day.  For the last five minutes at the end of each two hour 
period we will measure the work associated with breathing (work of breathing) and how well the chest and 
abdomen move up and down together as your baby breathes. To measure the work of breathing we place a tube 
similar to your baby’s nasogastric (feeding) tube through his/her mouth into the stomach. This allows us to 
measure the main breathing muscle, the diaphragm. To measure how well the chest and the abdomen move 
together as your baby breathes, we will put elasticated bands around his/her chest and the abdomen. You are 
welcome to be present during the procedure. 
 
Why has my baby been invited?  
 
Your baby is still requiring support for their breathing and is over two weeks old.  
 
Are there any disadvantages of taking part in the study? 
 
There are no known risks to your baby taking part in this study, indeed it will help us see which of the two 
methods of supporting your baby’s breathing is more helpful to your baby. The procedure may cause some 
discomfort and there may be some disturbance when changing the breathing apparatus, but every effort will be 






How will the information be shared? 
 
The results of the study will be given to the clinical staff looking after your baby and this will be one of 
the ways they to decide which method of breathing support will be better for your baby. We will, with 
your consent, inform your GP of your baby’s involvement in this study by stating it in your baby’s 
discharge summary. 
  
What will happen to the results of the study? 
 
The results of the research from all the babies that have been taken part will be analysed and the 
results made available to practitioners such as doctors, nurses and physiotherapists and may be used 
to guide the management of babies in the future. The results may be presented at national and 
international meetings and in peer reviewed medical journals for wider distribution. At no point will any 
information revealing your baby’s identity be made available to anyone outside the research team or 
the clinical team caring for him/her.   
 
What if there is a problem? 
 
There are no harmful side effects associated with this study. In the unlikely event that there is a 
problem King’s College, London and King's College Hospital indemnity will apply. 
 
What happens when the research stops? 
 
Once the required information has been collected from your baby, there is nothing further that you or 
your baby is required to do. Your baby would continue to receive their medical care as usual 
 
Who has reviewed the study? 
 
A regional Ethics committee (NRES London - Westminster Research Ethics Committee) has reviewed 




It is important you understand that this study is voluntary and for research purposes. You may choose 
not to allow your baby to participate in this study and you may withdraw your baby at any time without 
their medical care or legal rights being affected.  If you require any further information, please ask.  
 
If you decide to allow your baby to take part in the study, you will be given a copy of the information 
sheet and consent form to keep.  All information that is collected during the course of the research will 
be kept strictly confidential and if the results are published then anonymity will be maintained. This 
study was reviewed and approved by the Research Ethics Committee of King's College Hospital NHS 
Trust. 
 
Thank you very much for considering your baby for enrolment into this project. If you are happy to 
participate please sign below. If you have any further questions or would like to meet with a member of 










(15/01/2014, Version 1) 
 
Patient Identifier number    NB Three copies should be made, for 
for this trial:   ………………… (1) patient, (2) researcher, (3) hospital notes 
 
 
Title of Project: Work of breathing during HHFNC and CPAP 
                Please initial box 
3. I confirm that I have read and understand the information 
sheet dated 11/03/2014 for the above study and have 
had the opportunity to ask questions.  
 
4. I understand that my baby’s participation is voluntary and that I  
am free to withdraw at my baby at any time, without giving any  
reason, without my baby’s medical care or legal rights being affected. 
 
5. I understand that sections of any of my baby’s medical notes may  
be looked at by responsible individuals or from regulatory 
authorities where it is relevant to my taking part in research. 
I give permission for these individuals to have access to my baby’s 
records. 
 
7. I consent for my GP to be informed of my baby’s inclusion into the study 
 




Name of Baby   Date     
 
 
Name of person giving consent Date    Signature 
 
 










A3  Publications arising from this thesis 
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